Author: Editor

Marwan Fakih, MD, The Judy & Bernard Briskin Distinguished Director of Clinical Research; Professor, Department of Medical Oncology & Therapeutics Research; Associate Director for Clinical Research, Comprehensive Cancer Center; Medical Director, Judy & Bernard Briskin Center for Clinical Research; Co-director, Gastrointestinal Cancer Program at City of Hope. In this video, he speaks about Colorectal Cancer Awareness Month.

Bart Scott, MD, Professor, Transplantation Program, Clinical Research Division at Fred Hutchinson Cancer Research Center. In this video, he speaks about the Highlights of ASH 2022 – Hematopoietic Stem Cell Transplantation.   Hematopoietic stem cell transplantation (HSCT) is an intravenous infusion of hematopoietic stem cells used to restore blood cell production in individuals with damaged or dysfunctional bone marrow or immune systems. This approach has been utilized to treat a variety of malignant and nonmalignant disorders with increasing frequency during the last half-century.   Cells for HSCT can be taken from the patient (autologous transplant), a sibling or unrelated donor…

Bart Scott, MD, Professor, Transplantation Program, Clinical Research Division at Fred Hutchinson Cancer Research Center. In this video, he speaks about the Highlights of ASH 2022 – Hematopoietic Stem Cell Transplantation.   Hematopoietic stem cell transplantation (HSCT) is an intravenous infusion of hematopoietic stem cells used to restore blood cell production in individuals with damaged or dysfunctional bone marrow or immune systems. This approach has been utilized to treat a variety of malignant and nonmalignant disorders with increasing frequency during the last half-century.   Cells for HSCT can be taken from the patient (autologous transplant), a sibling or unrelated donor…

Kim Chi, MD, Vice President & Chief Medical Officer of BC Cancer speaks about TITAN: A final analysis with close to four years of follow-up data evaluating Erleada versus placebo in patients with metastatic castration-sensitive prostate cancer receiving hormone therapy (Abstract #11).   RARITAN, N.J. /PRNewswire/ — Janssen Pharmaceutical Inc., Feb. 2, 2021, Johnson & Johnson companies today reported that at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the clinical development program ERLEADA® (apalutamide), the depth of their solid tumor portfolio will be highlighted. The virtual…

Kim Chi, MD, Vice President & Chief Medical Officer of BC Cancer speaks about TITAN: A final analysis with close to four years of follow-up data evaluating Erleada versus placebo in patients with metastatic castration-sensitive prostate cancer receiving hormone therapy (Abstract #11).   RARITAN, N.J. /PRNewswire/ — Janssen Pharmaceutical Inc., Feb. 2, 2021, Johnson & Johnson companies today reported that at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the clinical development program ERLEADA® (apalutamide), the depth of their solid tumor portfolio will be highlighted. The virtual…

Toni Choueiri, MD, Director, Lank Center for Genitourinary Oncology, Director, Kidney Cancer Center, Senior Physician, Jerome and Nancy Kohlberg Chair and Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute. In this video, he speaks about the ASCO GU 2022 Abstract – Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564.

Toni Choueiri, MD, Director, Lank Center for Genitourinary Oncology, Director, Kidney Cancer Center, Senior Physician, Jerome and Nancy Kohlberg Chair and Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute. In this video, he speaks about the ASCO GU 2022 Abstract – Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564.  

Professor Amit Singal, Professor, Medical Director of the Liver Tumor Program, and Clinical Chief of Hepatology at University of Texas Southwestern Medical Center. In this video, he speaks about the ESMO Deep Dive 2022 – Primary and Secondary Prevention of Hepatocellular Carcinoma.    Hepatocellular Carcinoma -  This is the most frequent type of liver cancer. Hepatocellular carcinoma is most common in persons with liver disease, particularly chronic hepatitis B and C. Symptoms do not always develop in the early stages of cancer. Later symptoms include weight loss, upper abdominal pain, and skin discoloration (jaundice). Surgery, transplant, freezing or heating the…

Professor Amit Singal, Professor, Medical Director of the Liver Tumor Program, and Clinical Chief of Hepatology at University of Texas Southwestern Medical Center. In this video, he speaks about the ESMO Deep Dive 2022 – Primary and Secondary Prevention of Hepatocellular Carcinoma.  Hepatocellular Carcinoma -  This is the most frequent type of liver cancer. Hepatocellular carcinoma is most common in persons with liver disease, particularly chronic hepatitis B and C. Symptoms do not always develop in the early stages of cancer. Later symptoms include weight loss, upper abdominal pain, and skin discoloration (jaundice). Surgery, transplant, freezing or heating the cancer…

Shilpa Gupta, MD, Director of the Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic. In this video, she speaks about the ASCO GU 2022 Abstract – Disease management and frontline treatment of locally advanced or metastatic urothelial (la/mUC) carcinoma: The U.S. physician PARADIGM study. Origins: The therapy options for la/mUC are changing. There is a scarcity of data on current la/mUC therapy patterns. Using qualitative interviews, this study examined physician treatment decision-making and prescribing trends in the United States (QIs). Methodologies: First, published abstracts from January 2018 to March 2021 were…

Shilpa Gupta, MD, Director of the Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic. In this video, she speaks about the ASCO GU 2022 Abstract – Disease management and frontline treatment of locally advanced or metastatic urothelial (la/mUC) carcinoma: The U.S. physician PARADIGM study. Origins: The therapy options for la/mUC are changing. There is a scarcity of data on current la/mUC therapy patterns. Using qualitative interviews, this study examined physician treatment decision-making and prescribing trends in the United States (QIs). Methodologies: First, published abstracts from January 2018 to March 2021 were…

Guru Sonpavde, MD, Director of the bladder cancer program at Dana-Farber Cancer Institute and is on the faculty of Harvard Medical School at Harvard University. In this video, he speaks about the ASCO GU 2022 Abstract – Early changes in peripheral blood neutrophil-lymphocyte ratio (NLR) predicts outcomes with immune checkpoint inhibitors (ICIs) for metastatic urothelial carcinoma (mUC).   Origins: ICIs have made strides in the treatment of mUC. However, determining the objective effectiveness of ICIs via radiographic imaging might take months and can be muddled by pseudoprogression. Immune cells infiltrating the tumor microenvironment appear to be reflected in peripheral blood…

Guru Sonpavde, MD, Director of the bladder cancer program at Dana-Farber Cancer Institute and is on the faculty of Harvard Medical School at Harvard University. In this video, he speaks about the ASCO GU 2022 Abstract – Early changes in peripheral blood neutrophil-lymphocyte ratio (NLR) predicts outcomes with immune checkpoint inhibitors (ICIs) for metastatic urothelial carcinoma (mUC).     Origins:   ICIs have made strides in the treatment of mUC. However, determining the objective effectiveness of ICIs via radiographic imaging might take months and can be muddled by pseudoprogression. Immune cells infiltrating the tumor microenvironment appear to be reflected in…

Mya Roberson, Ph.D., Assistant Professor Health Policy at Vanderbilt University Medical School. In this video, she speaks about the article Let’s get critical: bringing Critical Race Theory into cancer research.   Critical Race Theory (CRT) was first defined in American academic legal study to describe the social creation of racial categories as a tool of oppression, as well as the systemic existence of racism in society. CRT is a term that refers to the societal power that allows one dominant socially constructed racial group to marginalize others, and it is not exclusive to the United States. Scholars in the health…

Mya Roberson, Ph.D., Assistant Professor Health Policy at Vanderbilt University Medical School. In this video, she speaks about the article Let’s get critical: bringing Critical Race Theory into cancer research.   Critical Race Theory (CRT) was first defined in American academic legal study to describe the social creation of racial categories as a tool of oppression, as well as the systemic existence of racism in society. CRT is a term that refers to the societal power that allows one dominant socially constructed racial group to marginalize others, and it is not exclusive to the United States. Scholars in the health…

Professor Fred Saad, MD, FRCS, Professor, and Chairman of Urology and Director of Genitourinary Oncology at the University of Montreal Hospital Center. In this video, he speaks about the ASCO GU 2022 Abstract – PROpel Phase III trial of Lynparza (olaparib) in combination with standard-of-care abiraterone.   Explanation in detail: PROpel is a phase III trial comparing the efficacy, safety, and tolerability of olaparib with placebo when given in combination with abiraterone to patients with metastatic castration-resistant prostate cancer (mCRPC) who have not previously received chemotherapy or novel hormonal agents (NHAs) (first-line setting). In PROpel, about 720 patients were to…

Professor Fred Saad, MD, FRCS, Professor, and Chairman of Urology and Director of Genitourinary Oncology at the University of Montreal Hospital Center. In this video, he speaks about the ASCO GU 2022 Abstract – PROpel Phase III trial of Lynparza (olaparib) in combination with standard-of-care abiraterone.   Explanation in detail: PROpel is a phase III trial comparing the efficacy, safety, and tolerability of olaparib with placebo when given in combination with abiraterone to patients with metastatic castration-resistant prostate cancer (mCRPC) who have not previously received chemotherapy or novel hormonal agents (NHAs) (first-line setting). In PROpel, about 720 patients were to…

Alicia K. Morgans, MD, MPH, Genitourinary Medical Oncologist, Medical Director of Survivorship Program Dana-Farber Cancer Institute. In this video, she speaks about the ASCO GU 2022 Abstract – 16: (Rapid Abstract Session A) Identifying patient profiles and mapping the patient journey across three countries in a large-scale, fully digital survey of patients with prostate cancer.     Origins:   A survey of PCa patients was done to map their experiences, expectations, and attitudes, as well as to identify obstacles and unmet needs in diagnosis, therapy patterns, care teams, QoL, patient groups, and resources. We provide the preliminary survey findings and…

Alicia K. Morgans, MD, MPH, Genitourinary Medical Oncologist, Medical Director of Survivorship Program Dana-Farber Cancer Institute. In this video, she speaks about the ASCO GU 2022 Abstract – 16: (Rapid Abstract Session A) Identifying patient profiles and mapping the patient journey across three countries in a large-scale, fully digital survey of patients with prostate cancer.     Origins:   A survey of PCa patients was done to map their experiences, expectations, and attitudes, as well as to identify obstacles and unmet needs in diagnosis, therapy patterns, care teams, QoL, patient groups, and resources. We provide the preliminary survey findings and…

Chris Schaber is Focused on Rare and Orphan Diseases with High Unmet Medical Need We recently spoke to Dr. Chris Schaber, President & CEO, Soligenix, Inc. on OncologyTube.  Soligenix (Nasdaq: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Dr. Schaber is extremely optimistic about the future of medicine and the progress he and his team are making with the Soligenix drug pipeline – especially their lead product called HyBryteâ„¢ for a devastating blood and skin cancer. HyBryteâ„¢ (SGX301 or synthetic hypericin) is a unique drug…

Bailey Gleason Fitzgerald, MD, Fellow, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai. In this video, she speaks about the IASLC 2022 Abstract Rapid Progression of Metastatic NSCLC treated with First Line Osimertinib: An Institutional Case Series.   Origins:   For patients with EGFR exon 19 or 21 mutant non-small cell lung cancer in the United States, osimertinib is the conventional first-line (1L) tyrosine kinase inhibitor (TKI) (NSCLC). The median PFS in the FLAURA study of 1L osimertinib was 18.9 months. However, the ORR was only 80%, indicating that 1L osimertinib may not be beneficial to a…

Bailey Gleason Fitzgerald, MD, Fellow, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai. In this video, she speaks about the IASLC 2022 Abstract Rapid Progression of Metastatic NSCLC treated with First Line Osimertinib: An Institutional Case Series.   Origins:   For patients with EGFR exon 19 or 21 mutant non-small cell lung cancer in the United States, osimertinib is the conventional first-line (1L) tyrosine kinase inhibitor (TKI) (NSCLC). The median PFS in the FLAURA study of 1L osimertinib was 18.9 months. However, the ORR was only 80%, indicating that 1L osimertinib may not be beneficial to a…

Miguel Garcia, MD, Clinical Research Fellow, Division of Medical Oncology & Hematology at University Health Network. In this video, he speaks about the IASLC 2022 Abstract – Accelerating Lung Cancer Diagnosis and Molecular Profiling through Liquid Biopsy.   Origins:   In advanced non-small cell lung cancer, molecular profiling of tumor tissue is the gold standard for therapeutic decision-making. However, due to a lack of biopsy samples, results are frequently delayed or unavailable. By finding circulating tumor DNA (ctDNA) in plasma, liquid biopsies can help with genotyping. As part of the pre-diagnostic work-up for lung cancer, we tested the use of…

Miguel Garcia, MD, Clinical Research Fellow, Division of Medical Oncology & Hematology at University Health Network. In this video, he speaks about the IASLC 2022 Abstract – Accelerating Lung Cancer Diagnosis and Molecular Profiling through Liquid Biopsy.   Origins:   In advanced non-small cell lung cancer, molecular profiling of tumor tissue is the gold standard for therapeutic decision-making. However, due to a lack of biopsy samples, results are frequently delayed or unavailable. By finding circulating tumor DNA (ctDNA) in plasma, liquid biopsies can help with genotyping. As part of the pre-diagnostic work-up for lung cancer, we tested the use of…

Kevin R. Krull, Ph.D., Member, St. Jude Faculty, Endowed Chair in Cancer Survivorship at St. Jude Children’s Research Hospital. In this video, he speaks about the article in ASH Clinical News – Long-Term Childhood Hodgkin Lymphoma Survivors Have Increased Risk of Neurocognitive Impairment.     Neurocognitive impairment is more common in long-term survivors of juvenile Hodgkin lymphoma (HL). According to a study published in Blood, exercise and smoking are modifiable risk factors for this impairment that could be used as therapy targets to improve functional results.   A total of 1,781 adult HL survivors were enrolled in the multi-institutional Childhood…

Survivors of childhood Hodgkin’s Lymphoma have been an unrecognized group for a number of years because they don’t receive direct neurotoxic therapies. So, children’s oncology groups in North America define neurotoxic exposures as cranial radiation, high dose intrathecal, or methotrexate; high dose, intravenous methotrexate, or cytarabine and neurosurgery and Hodgkin’s Lymphoma survivors don’t receive any of them. They’ve been unrecognized as a risk group for a number of years. However, we see that they struggle when they hit adulthood. And we’ve been looking at their cognitive function in a number of ways. We see that they do develop problems with…

Jeroen Roose, Ph.D., Principal Investigator, and Hugo Gonzalez Velozo, Ph.D., Postdoctoral Fellow at UC San Francisco. This video talks about their study “Cellular architecture of human brain metastases,” which is a single-cell analysis of huma BrM that reveals multiple conserved features across multiple cancer and points the way to potential future improvements in immune therapies. With thanks to Joanna Phillips, MD, Ph.D., and Matthew Spitzer, Ph.D., who collaborated with Dr. Gonzalez Velozo. All this could not be possible without the late Zena Werb, Ph.D., for starting this with her visions for the future treatment.   “What we haven’t looked at…

Jeroen Roose, Ph.D., Principal Investigator, and Hugo Gonzalez Velozo, Ph.D., Postdoctoral Fellow at UC San Francisco. This video talks about their study “Cellular architecture of human brain metastases, ” which is a single-cell analysis of huma BrM that reveals multiple conserved features across multiple cancer and points the way to potential future improvements in immune therapies. With thanks to Joanna Phillips, MD, Ph.D., and Matthew Spitzer, Ph.D., who collaborated with Dr. Gonzalez Velozo. All this could not be possible without the late Zena Werb, Ph.D., for starting this with her visions for the future treatment.   “What we haven’t looked…

Rebecca Harrison, MD, Assistant Professor of Neuro-Oncology at MD Anderson and is now a Clinical Associate Professor BC Cancer the University of British Columbia. In this video, she speaks about the Neurologic Toxicities of Immunotherapy.   Overview:   Over the last two decades, immunotherapy has changed cancer treatment. Immunotherapy techniques’ anticancer results come at the cost of an increasing range of immune-related adverse events (irAEs) caused by cross-reactivity between tumor and normal host tissue. These negative events can occur in any organ and range in severity from moderate to severe, even life-threatening. While neurological irAEs linked with immune checkpoint inhibitors…

Rebecca Harrison, MD, Assistant Professor of Neuro-Oncology at MD Anderson and is now a Clinical Associate Professor BC Cancer the University of British Columbia. In this video, she speaks about the Neurologic Toxicities of Immunotherapy.   Overview:   Over the last two decades, immunotherapy has changed cancer treatment. Immunotherapy techniques’ anticancer results come at the cost of an increasing range of immune-related adverse events (irAEs) caused by cross-reactivity between tumor and normal host tissue. These negative events can occur in any organ and range in severity from moderate to severe, even life-threatening. While neurological irAEs linked with immune checkpoint inhibitors…

Daniel Rotroff, Ph.D., MSPH, senior author of the study and researcher in the Department of Quantitative Health Sciences with Cleveland Clinic’s Lerner Research Institute. Dr. Rotroff conducted the research in collaboration with Dr. Frederico Aucejo, Director of the Liver Tumor Clinic at Cleveland Clinic; and Mrs. Arshiya Mariam, lead author of the study. In this video, he speaks about Salivary miRNAs as non-invasive biomarkers of hepatocellular carcinoma: a pilot study.   Overview: Origins: Current detection approaches for hepatocellular carcinoma (HCC), such as alpha fetoprotein (AFP) and ultrasound, are ineffective due to their low sensitivity. MicroRNAs (miRNAs) are short non-coding RNAs…

Daniel Rotroff, Ph.D., MSPH, senior author of the study and researcher in the Department of Quantitative Health Sciences with Cleveland Clinic’s Lerner Research Institute. Dr. Rotroff conducted the research in collaboration with Dr. Frederico Aucejo, Director of the Liver Tumor Clinic at Cleveland Clinic; and Mrs. Arshiya Mariam, lead author of the study. In this video, he speaks about Salivary miRNAs as non-invasive biomarkers of hepatocellular carcinoma: a pilot study.     Overview:   Origins:   Current detection approaches for hepatocellular carcinoma (HCC), such as alpha fetoprotein (AFP) and ultrasound, are ineffective due to their low sensitivity. MicroRNAs (miRNAs) are…

John Strickler, MD, Associate Professor of Medicine, Member of the Duke Cancer Institute at Duke University. In this video, he speaks about the ASCO Plenary Series 2022 – Abstract 360490: First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety.   Brief Synopsis:   In adult individuals with KRAS p.G12C mutant advanced solid tumors, assess the safety and tolerability of AMG 510.   In adult participants with KRAS p.G12C mutant advanced solid tumors, calculate the maximum tolerated dosage (MTD) and/or a recommended phase 2 dose (RP2D).

John Strickler, MD, Associate Professor of Medicine, Member of the Duke Cancer Institute at Duke University. In this video, he speaks about the ASCO Plenary Series 2022 – Abstract 360490: First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety.   Brief Synopsis:   In adult individuals with KRAS p.G12C mutant advanced solid tumors, assess the safety and tolerability of AMG 510.   In adult participants with KRAS p.G12C mutant advanced solid tumors, calculate the maximum tolerated dosage (MTD) and/or a recommended phase 2 dose (RP2D).

Wendy Chen, MD, MPH, Assistant Professor, Medicine, Harvard Medical School, Senior Physician, Breast Oncology Center, Dana-Farber Cancer Institute. In this video, she speaks about ASCO Plenary 2022 – Abstract 360922: A randomized phase III, double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) Trial.   Description in detail:   In early-stage node-positive HER2 negative breast cancer patients, this is a randomized double-blind placebo-controlled phase III trial of aspirin (300 mg daily). Hormone Receptor status (HR positive vs HR negative), body mass index (30 vs 30 kg/m2), and stage will all be…

Wendy Chen, MD, MPH, Assistant Professor, Medicine, Harvard Medical School, Senior Physician, Breast Oncology Center, Dana-Farber Cancer Institute. In this video, she speaks about ASCO Plenary 2022 – Abstract 360922: A randomized phase III, double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) Trial.   Description in detail:   In early-stage node-positive HER2 negative breast cancer patients, this is a randomized double-blind placebo-controlled phase III trial of aspirin (300 mg daily). Hormone Receptor status (HR positive vs HR negative), body mass index (30 vs 30 kg/m2), and stage will all be…

Dr. Schiff is the Harrison Distinguished Professor of Neurology, Neurological Surgery, and Medicine. He is the co-director of the UVA Neuro-Oncology Center at UVA Health. His specialties include clinical trials for malignant brain tumors and the management of neurological complications of cancer and its therapies. He has led or co-led numerous NCI-funded brain tumor and pharmaceutical clinical trials.   Dr. Schiff serves on the NCI brain malignancy steering committee and chairs the ECOG-ACRIN brain tumor, working group. He also serves on several editorial boards, most notably as the associate editor of the journal, Neuro-Oncology.    In this video, he speaks…

Dr. Schiff is the Harrison Distinguished Professor of Neurology, Neurological Surgery, and Medicine. He is the co-director of the UVA Neuro-Oncology Center at UVA Health. His specialties include clinical trials for malignant brain tumors and the management of neurological complications of cancer and its therapies. He has led or co-led numerous NCI-funded brain tumor and pharmaceutical clinical trials.   Dr. Schiff serves on the NCI brain malignancy steering committee and chairs the ECOG-ACRIN brain tumor, working group. He also serves on several editorial boards, most notably as the associate editor of the journal, Neuro-Oncology.    In this video, he speaks…

Charles Lopez, MD, Ph.D., Associate Professor of Medicine, School of Medicine Cell and Developmental Biology Graduate Program, School of Medicine, Cancer Biology Graduate Program, School of Medicine Program in Molecular and Cellular Biosciences, School of Medicine at Oregon Health & Science University (OHSU). In this video, he speaks about the ASCU GI 2022 Abstract – NeoOPTIMIZE: An open-label, phase II trial and biomarker discovery platform to assess the efficacy of adaptive switching of modified FOLFIRINOX (mFFX) or gemcitabine/nab-paclitaxel (GA) as a neoadjuvant strategy for patients with resectable/borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).   Origins:   Patients…

Charles Lopez, MD, Ph.D., Associate Professor of Medicine, School of Medicine Cell and Developmental Biology Graduate Program, School of Medicine, Cancer Biology Graduate Program, School of Medicine Program in Molecular and Cellular Biosciences, School of Medicine at Oregon Health & Science University (OHSU). In this video, he speaks about the ASCU GI 2022 Abstract – NeoOPTIMIZE: An open-label, phase II trial and biomarker discovery platform to assess the efficacy of adaptive switching of modified FOLFIRINOX (mFFX) or gemcitabine/nab-paclitaxel (GA) as a neoadjuvant strategy for patients with resectable/borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).   Origins:   Patients…

Chirag Shah, MD, Director of Breast Radiation Oncology and Director of Clinical Research in the Department of Radiation Oncology at Cleveland Clinic. In this video, he speaks about the abstract – A Comparison of Bioimpedance Spectroscopy or Tape Measure Triggered Compression Intervention in Chronic Breast Cancer Lymphedema Prevention.   Overview – Origins: Following a subclinical lymphedema (S-BCRL) intervention triggered by bioimpedance spectroscopy (BIS) or tape measurement, rates of progression to chronic breast cancer-related lymphedema (defined as a 10% arm volume change from baseline requiring complex decongestive physiotherapy [CDP]) were compared (TM). Findings and Methodologies: New breast cancer patients undergoing mastectomy/partial…

Chirag Shah, MD, Director of Breast Radiation Oncology and Director of Clinical Research in the Department of Radiation Oncology at Cleveland Clinic. In this video, he speaks about the abstract – A Comparison of Bioimpedance Spectroscopy or Tape Measure Triggered Compression Intervention in Chronic Breast Cancer Lymphedema Prevention.   Overview – Origins: Following a subclinical lymphedema (S-BCRL) intervention triggered by bioimpedance spectroscopy (BIS) or tape measurement, rates of progression to chronic breast cancer-related lymphedema (defined as a 10% arm volume change from baseline requiring complex decongestive physiotherapy [CDP]) were compared (TM). Findings and Methodologies: New breast cancer patients undergoing mastectomy/partial…

Christian Rolfo, MD, Ph.D., MBA, Dr.hc., Professor of Medicine (Hematology and Medical Oncology) and Associate Director for Clinical Research in the Center for Thoracic Oncology at Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Medical System & Icahn School of Medicine, Mount Sinai. In this video, he speaks about Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?   Overview:   Agents that target immunological checkpoints have shown promise in improving therapy outcomes in patients with lung cancer in a variety of clinical settings over the last few years. The FDA has approved PD-1/PD-L1 inhibitors alone…

Christian Rolfo, MD, Ph.D., MBA, Dr.hc., Professor of Medicine (Hematology and Medical Oncology) and Associate Director for Clinical Research in the Center for Thoracic Oncology at Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Medical System & Icahn School of Medicine, Mount Sinai. In this video, he speaks about Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?     Overview:   Agents that target immunological checkpoints have shown promise in improving therapy outcomes in patients with lung cancer in a variety of clinical settings over the last few years. The FDA has approved PD-1/PD-L1 inhibitors…

Srdan Verstovsek, MD, Ph.D., Professor, Department of Leukemia at MD Anderson Cancer Center. In this video, he speaks about Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis. Sierra Oncology, Inc., a late-stage biopharmaceutical company focused on developing targeted therapies for rare cancers, today announced positive topline data from the pivotal Phase 3 MOMENTUM study, a global, randomized, double-blind clinical trial evaluating momelotinib (MMB) in myelofibrosis patients who are symptomatic and anemic and have previously received an approved JAK inhibitor. All of the trial ‘s primary and secondary…

Srdan Verstovsek, MD, Ph.D., Professor, Department of Leukemia at MD Anderson Cancer Center. In this video, he speaks about Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis. Sierra Oncology, Inc., a late-stage biopharmaceutical company focused on developing targeted therapies for rare cancers, today announced positive topline data from the pivotal Phase 3 MOMENTUM study, a global, randomized, double-blind clinical trial evaluating momelotinib (MMB) in myelofibrosis patients who are symptomatic and anemic and have previously received an approved JAK inhibitor. All of the trial ‘s primary and secondary…

Sepideh Gholami, MD, MAS, FACS, Liver and Pancreas Surgeon at UC Davis Medical Center, Cancer Researcher at UC Davis Health. In this video, she speaks about the ASCO GI 2022 Panel Discussion – Rapid Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract.

Sepideh Gholami, MD, MAS, FACS, Liver and Pancreas Surgeon at UC Davis Medical Center, Cancer Researcher at UC Davis Health. In this video, she speaks about the ASCO GI 2022 Panel Discussion – Rapid Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract.

Thomas Abrams, MD, Assistant Professor of Medicine at Dana-Farber Cancer Institute. In this video, he speaks about the ASCO GI 2022 Abstract – A phase 1b multitumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors (COSMIC-021): Results of the colorectal cancer cohort.     Origins:   Cabozantinib, a multiple receptor tyrosine kinase inhibitor, provides an immunological-permissive milieu, which may help immune checkpoint inhibitors work more effectively. The combination of cabozantinib and atezolizumab, an anti-PD-L1 agent, is being tested in COSMIC-021 (NCT03170960) in patients with advanced solid malignancies. The researchers present the results of patients with metastatic colorectal cancer…

Thomas Abrams, MD, Assistant Professor of Medicine at Dana-Farber Cancer Institute. In this video, he speaks about the ASCO GI 2022 Abstract – A phase 1b multitumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors (COSMIC-021): Results of the colorectal cancer cohort.     Origins:   Cabozantinib, a multiple receptor tyrosine kinase inhibitor, provides an immunological-permissive milieu, which may help immune checkpoint inhibitors work more effectively. The combination of cabozantinib and atezolizumab, an anti-PD-L1 agent, is being tested in COSMIC-021 (NCT03170960) in patients with advanced solid malignancies. The researchers present the results of patients with metastatic colorectal cancer…

Nazanin Majd, MD, Ph.D., BS, Assistant Professor, Department of Neuro-Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, Houston, TX. In this video, she speaks about Immunotherapy for Neuro-oncology.    Abstract   Immunotherapy is at the forefront of cancer advances and has revolutionized the landscape of treatment for many solid and hematological malignancies. Several factors unique to the central nervous system (CNS), such as limited space for an inflammatory response, difficulties with repeated sampling, corticosteroid use for cerebral edema management, and immunosuppressive mechanisms within the tumor and brain parenchyma, have all posed challenges in the…

Nazanin Majd, MD, Ph.D., BS, Assistant Professor, Department of Neuro-Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, Houston, TX. In this video, she speaks about Immunotherapy for Neuro-oncology.    Abstract   Immunotherapy is at the forefront of cancer advances and has revolutionized the landscape of treatment for many solid and hematological malignancies. Several factors unique to the central nervous system (CNS), such as limited space for an inflammatory response, difficulties with repeated sampling, corticosteroid use for cerebral edema management, and immunosuppressive mechanisms within the tumor and brain parenchyma, have all posed challenges in the…

Karyn A Goodman, MD, MS, Professor of Radiation Oncology, Professor of Medicine, Hematology and Medical Oncology at Icahn School of Medicine at Mount Sinai. In this video, she speaks about SKYSCRAPER-07: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy.     Origins:   Patients with unresectable, locally advanced esophageal squamous cell carcinoma (ESCC) are currently treated with definitive platinum-based concomitant chemoradiotherapy (dCRT). However, ESCC has a dismal prognosis, with more than half of tumors recurring following dCRT (Smyth et al. Nat Rev…

Karyn A Goodman, MD, MS, Professor of Radiation Oncology, Professor of Medicine, Hematology and Medical Oncology at Icahn School of Medicine at Mount Sinai. In this video, she speaks about SKYSCRAPER-07: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy.     Origins:   Patients with unresectable, locally advanced esophageal squamous cell carcinoma (ESCC) are currently treated with definitive platinum-based concomitant chemoradiotherapy (dCRT). However, ESCC has a dismal prognosis, with more than half of tumors recurring following dCRT (Smyth et al. Nat Rev…

Vincent J. Picozzi Jr, MD, Hematologist/Oncologist from Virginia Mason Medical Center. In this interview, he speaks about the ASCO GI 2022 Abstract – PANOVA-3: A phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic adenocarcinoma.   Origins:   Tumor Treating Fields (TTFields) is a non-invasive, loco-regional antimitotic therapy for glioblastoma and malignant pleural mesothelioma. TTFields (150–200 kHz) are given to the tumor site via arrays implanted on the skin. TTFields (150 kHz) demonstrated antiproliferative and anticlonogenic effects on pancreatic cancer cells in vitro, with or without treatment. In both…

Vincent J. Picozzi Jr, MD, Hematologist/Oncologist from Virginia Mason Medical Center. In this interview, he speaks about the ASCO GI 2022 Abstract – PANOVA-3: A phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic adenocarcinoma.   Origins:   Tumor Treating Fields (TTFields) is a non-invasive, loco-regional antimitotic therapy for glioblastoma and malignant pleural mesothelioma. TTFields (150–200 kHz) are given to the tumor site via arrays implanted on the skin. TTFields (150 kHz) demonstrated antiproliferative and anticlonogenic effects on pancreatic cancer cells in vitro, with or without treatment. In both…

Diana Hanna, MD is the Program Director over Hoag’s Phase 1 Cancer Research within the Hoag Family Cancer Institute. Dr. Hanna completed her medical schooling at the University of California, Davis, as well as her internship and residency. She then completed a fellowship in hematology/oncology at the University of Southern California. Dr. Hanna provides oversight for all of Hoag’s Phase 1, or early therapeutic, clinical trials. In this video, she speaks about the ASCO GI 2022 Abstract – Randomized phase II trial of two different nutritional approaches for patients receiving treatment for their advanced pancreatic cancer.     Origins:  …

Diana Hanna, MD is the Program Director over Hoag’s Phase 1 Cancer Research within the Hoag Family Cancer Institute. Dr. Hanna completed her medical schooling at the University of California, Davis, as well as her internship and residency. She then completed a fellowship in hematology/oncology at the University of Southern California. Dr. Hanna provides oversight for all of Hoag’s Phase 1, or early therapeutic, clinical trials. In this video, she speaks about the ASCO GI 2022 Abstract – Randomized phase II trial of two different nutritional approaches for patients receiving treatment for their advanced pancreatic cancer.     Origins:  …

In this video series, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss, and Dr. Ben Levy have continued candid discussions regarding cancer and COVID-19.In this continued time of social distancing and limiting clinic exposure, the doctors sat down to virtually discuss some of the questions we all hear regarding these unprecedented times, and how they affect primarily cancer patients.In this video, the discussion continues regarding telemedicine compared to in-person intervention, and what we have learned. Thanks to #Exelixis and #Merck for their support of this program. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

In this video series, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss, and Dr. Ben Levy have continued candid discussions regarding cancer and COVID-19.In this continued time of social distancing and limiting clinic exposure, the doctors sat down to virtually discuss some of the questions we all hear regarding these unprecedented times, and how they affect primarily cancer patients.In this video, the discussion is surrounding telemedicine and it’s evolving place in the oncology world. Thanks to #Exelixis and #Merck for their support of this program. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

In this video series, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss, and Dr. Ben Levy have continued candid discussions regarding cancer and COVID-19.In this continued time of social distancing and limiting clinic exposure, the doctors sat down to virtually discuss some of the questions we all hear regarding these unprecedented times, and how they affect primarily cancer patients.In this video, the discussion is surrounding the communities opening up, masking, and safety.Thanks to #Exelixis and #Merck for their support of this program. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

In this video series, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss, and Dr. Ben Levy have continued candid discussions regarding cancer and COVID-19.In this continued time of social distancing and limiting clinic exposure, the doctors sat down to virtually discuss some of the questions we all hear regarding these unprecedented times, and how they affect primarily cancer patients.In this video, the discussion is surrounding the role of the Oncologists in education for patients during the pandemic.Thanks to #Exelixis and #Merck for their support of this program. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

In this video series, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss, and Dr. Ben Levy have continued candid discussions regarding cancer and COVID-19.In this continued time of social distancing and limiting clinic exposure, the doctors sat down to virtually discuss some of the questions we all hear regarding these unprecedented times, and how they affect primarily cancer patients.In this video, the discussion is surrounding the variable acceptance of the COVID19 vaccine. Thanks to #Exelixis and #Merck for their support of this program. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this series, Dr. Gupta discusses Metastatic Triple-Negative Breast Cancer with Dr. Aditya Bardai. Dr. Bardai is Assistant Professor of Medicine at Harvard Medical School and Attending Physician in Medical Oncology at Massachusetts General Hospital. In this video, Drs. Gupta and Bardai discuss Metastatic Triple-Negative Breast Cancer and Targeted Therapy Treatment Options and Potential Side Effects #breastcancer #Metastases #triplenegative #cancerGRACE #genentech #lillyTo join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.

Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this series, Dr. Gupta discusses Metastatic Triple-Negative Breast Cancer with Dr. Aditya Bardai. Dr. Bardai is Assistant Professor of Medicine at Harvard Medical School and Attending Physician in Medical Oncology at Massachusetts General Hospital. In this video, Drs. Gupta and Bardai discuss Metastatic Triple-Negative Breast Cancer and Immunotherapy Treatment Options and Potential Side Effects #breastcancer #Metastases #triplenegative #cancerGRACE #genentech #lillyTo join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.

Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Brain Metastases in Breast Cancer with Dr. Jessica Young. In this video, Drs. Gupta and Young discuss what to expect after surgery.#breastcancer #Metastases #brainmets #cancerGRACE #genentech #lillyFor more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Brain Metastases in Breast Cancer with Dr. Jessica Young. In this video, Drs. Gupta and Young discuss what to expect during surgery. #breastcancer #surgery #cancerGRACE #genentech #lillyFor more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Brain Metastases in Breast Cancer with Dr. Nancy Lin. Dr. Lin is Associate Chief, Division of Breast Oncology at the Susan F. Smith Center for Women’s Cancers, Associate Professor of Medicine and the Director for the Metastatic Breast Cancer Program and the Program for Patients with Breast Cancer Brain Metastases at HarvardIn this video, Drs. Gupta and Lin discuss Brain Metastases in Breast Cancer and treatment options for patients…

Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Brain Metastases in Breast Cancer with Dr. Nancy Lin. Dr. Lin is Associate Chief, Division of Breast Oncology at the Susan F. Smith Center for Women’s Cancers, Associate Professor of Medicine and the Director for the Metastatic Breast Cancer Program and the Program for Patients with Breast Cancer Brain Metastases at HarvardIn this video, Drs. Gupta and Lin discuss Brain Metastases in Breast Cancer and treatment options and efficacy.#breastcancer…

Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021. For this series, the doctors discuss new trials for patients with NSCLC. In this video, the doctors discuss circulatory DNA. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021. For this series, the doctors discuss new trials for patients with NSCLC. In this video, the doctors discuss Lurbinectedin in SCLC and the failed ATLANTIS Trial. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021. For this series, the doctors discuss new trials for patients with NSCLC. In this video, the doctors discuss the MYLUNG Consortium and overall biomarker testing, as presented at the 2021 ASCO Annual Meeting. The MYLUNG study focused on U.S. Oncology Network community practices, where rates of patients having been tested for five major biomarkers (ALK, BRAF, EGFR, PD-L1, and ROS-1) show as less than 50%. A second study also showed that 39% of Black patients with metastatic NSCLC underwent…

Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021. For this series, the doctors discuss new trials for patients with NSCLC. The doctors discuss IMpower010, and Adjuvant Atezolizumab After Chemotherapy in Resected Stage I-IIIA NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021. For this series, the doctors discuss new trials for patients with NSCLC. In this video, the doctors discuss Amivantamab and Mobocertinib for EGFR Exon 20. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021. For this series, the doctors discuss new trials for patients with NSCLC. In this video, the doctors discuss CodeBreak 100, a phase 1/2 study evaluating the safety, tolerability, PK, and efficacy of Sotorasib (AMG 510) in patients with solid tumors with a specific KRAS mutation. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021. For this series, the doctors discuss new trials for patients with NSCLC. In this video, the doctors discuss immune therapy for brain metastasis. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021. For this series, the doctors discuss new trials for patients with NSCLC. In this video, the doctors discuss Carbo/Pemetrexed/Pembro in EGFRm+ or ALK+ NSCLC Acquired Resistance to Targeted Therapy For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021. For this series, the doctors discuss new trials for patients with NSCLC. The doctors discuss the Poseidon Trial, a Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy + Standard of care (SoC) chemotherapy or durvalumab monotherapy + SoC chemotherapy versus SoC chemotherapy alone as first line treatment in patients with metastatic non small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK)…

Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021. For this series, the doctors discuss new trials for patients with NSCLC. The doctors discuss the FDA Analysis of Immunotherapy +/- Chemotherapy in Patients with Advanced NSCLC and Low Tumor PD-L1 Expression For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021. For this series, the doctors discuss new trials for patients with NSCLC. The doctors discuss CheckMate 816, the addition of Nivolumab as neoadjuvant therapy in Early Stage NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021. For this series, the doctors discuss new trials for patients with NSCLC. The doctors discuss IMpower010, and Adjuvant Atezolizumab After Chemotherapy in Resected Stage I-IIIA NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

¡El video completo del Foro de Pacientes de Terapias Dirigidas 2021, presentado en español, ya está disponible! Este foro en vivo en línea se presentó el 22 de julio de 2021, con los mejores oncólogos en su campo presentando la información más actual y emergente en terapias dirigidas y respondiendo las preguntas de los pacientes en tiempo real. Para obtener más detalles, consulte la agenda completa: https://cancergrace.org/2021-spanish-targeted-therapies-patient-forum y la información de la facultad para obtener más información: https://cancergrace.org/faculty-2021-spanish-targeted-therapies-patient-forum Para obtener más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum. ********************************** The full video for the 2021 Targeted Therapies…

Kristen Renee Spencer, DO, MPH, is a medical oncologist in the Liver Cancer and Bile Duct Cancer Program and Phase I/Investigational Therapeutics Program at Rutgers Cancer Institute of New Jersey; and an assistant professor of medicine at Rutgers Robert Wood Johnson Medical School. In this video, she speaks about the ASCO GI 2022 Abstract – Novel Approaches in the Treatment Spectrum of Biliary Tract Cancers. Click here to read the full article

Kristen Renee Spencer, DO, MPH, is a medical oncologist in the Liver Cancer and Bile Duct Cancer Program and Phase I/Investigational Therapeutics Program at Rutgers Cancer Institute of New Jersey; and an assistant professor of medicine at Rutgers Robert Wood Johnson Medical School. In this video, she speaks about the ASCO GI 2022 Abstract – Novel Approaches in the Treatment Spectrum of Biliary Tract Cancers. Click here to listen to the related podcast

Dr. Zev Wainberg is the Co-Director UCLA Gastro-Intestinal Oncology Program; Medical Director, UCLA Colorectal Cancer Center; Professor of Medicine, Division of Hematology, Oncology, David Geffen School of Medicine at UCLA. In this video, he speaks about the ASCO GI 2022 Abstract – ASCO GI 2022 entitled Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.   Origins: Pembrolizumab (pembro) as monotherapy and in combination with chemotherapy (chemo) versus chemo as first-line therapy for PD-L1–positive (combined positive score [CPS] 1) advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma is being studied…

Dr. Zev Wainberg is the Co-Director UCLA Gastro-Intestinal Oncology Program; Medical Director, UCLA Colorectal Cancer Center; Professor of Medicine, Division of Hematology, Oncology, David Geffen School of Medicine at UCLA. In this video, he speaks about the ASCO GI 2022 Abstract – ASCO GI 2022 entitled Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.   Origins: Pembrolizumab (pembro) as monotherapy and in combination with chemotherapy (chemo) versus chemo as first-line therapy for PD-L1–positive (combined positive score [CPS] 1) advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma is being studied…

Dr. Zev Wainberg is the Co-Director UCLA Gastro-Intestinal Oncology Program; Medical Director, UCLA Colorectal Cancer Center; Professor of Medicine, Division of Hematology, Oncology, David Geffen School of Medicine at UCLA. In this video, he gives his comments about ASCO GI 2022 Enhertu studies.

Dr. Zev Wainberg is the Co-Director UCLA Gastro-Intestinal Oncology Program; Medical Director, UCLA Colorectal Cancer Center; Professor of Medicine, Division of Hematology, Oncology, David Geffen School of Medicine at UCLA. In this video, he gives his comments about ASCO GI 2022 Enhertu studies.

Alessandra Prete, MD, Oncologist at Istituto Oncologico Veneto in Padua. In this video, she speaks about the ASCO GI 2022 Abstract – Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the “CARACAS” study.   Origins: Advanced squamous cell anal cancer (aSCAC) is a rare and aggressive cancer with a poor prognosis and a high rate of morbidity. There are currently no targeted medicines available, and no standard treatments have been approved after the first line. Previous phase I/II trials using immune checkpoint inhibitors (ICI) showed evidence of efficacy, but predictive and…

Alessandra Prete, MD, Oncologist at Istituto Oncologico Veneto in Padua. In this video, she speaks about the ASCO GI 2022 Abstract – Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the “CARACAS” study.   Origins: Advanced squamous cell anal cancer (aSCAC) is a rare and aggressive cancer with a poor prognosis and a high rate of morbidity. There are currently no targeted medicines available, and no standard treatments have been approved after the first line. Previous phase I/II trials using immune checkpoint inhibitors (ICI) showed evidence of efficacy, but predictive and…

Thomas Marron, MD, Ph.D., Director of the Early Phase Trials Unit, Associate Professor of Medicine at Icahn School of Medicine at Mount Sinai. In this video, he speaks about Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.   Overview: Background Early-stage hepatocellular carcinoma is routinely surgically resected; nevertheless, most tumors return after surgery, and no perioperative intervention has been found to improve survival. Neoadjuvant immunotherapy has generated pathological responses in a variety of tumor types and may reduce the likelihood of hepatocellular carcinoma recurrence after surgery. The goal of this study was to see how well…

Thomas Marron, MD, Ph.D., Director of the Early Phase Trials Unit, Associate Professor of Medicine at Icahn School of Medicine at Mount Sinai. In this video, he speaks about Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.   Overview: Background Early-stage hepatocellular carcinoma is routinely surgically resected; nevertheless, most tumors return after surgery, and no perioperative intervention has been found to improve survival. Neoadjuvant immunotherapy has generated pathological responses in a variety of tumor types and may reduce the likelihood of hepatocellular carcinoma recurrence after surgery. The goal of this study was to see how well…

Amir Jazaeri, MD, Professor, Vice Chair, Clinical Research, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery at MD Anderson Cancer Center. In this video, he speaks about Immuno-Oncology for Gynecologic Malignancies.   Overview:   Currently, available cytotoxic and targeted therapy provide minimal benefit to patients with advanced and/or recurrent gynecologic malignancies. Immunotherapy’s success in other difficult-to-treat cancers, including metastatic melanoma and advanced lung cancer, has sparked a surge of interest in clinical trials in patients with gynecologic tumors. The FDA-approved use of immune checkpoint inhibitors in gynecologic oncology is currently confined to tumors with high microsatellite instability, cancers…

Amir Jazaeri, MD, Professor, Vice Chair, Clinical Research, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery at MD Anderson Cancer Center. In this video, he speaks about Immuno-Oncology for Gynecologic Malignancies.   Overview: Currently, available cytotoxic and targeted therapy provide minimal benefit to patients with advanced and/or recurrent gynecologic malignancies. Immunotherapy’s success in other difficult-to-treat cancers, including metastatic melanoma and advanced lung cancer, has sparked a surge of interest in clinical trials in patients with gynecologic tumors. The FDA-approved use of immune checkpoint inhibitors in gynecologic oncology is currently confined to tumors with high microsatellite instability, cancers with…

Susanna Ulahannan, MD, MMEd, Assistant Professor, Associate Director Phase 1 Unit at University Of Oklahoma Health Sciences Center. In this video, she speaks about the ASCO GI 2022 Abstract – Ezabenlimab (BI 754091), an anti-PD-1 antibody, in combination with BI 836880, a VEGF/Ang2-blocking nanobody, in patients (pts) with advanced colorectal cancer (CRC).   Origins:   Anti-PD-1 antibodies may work in tandem with other immunomodulatory or targeted drugs. The combination of ezabenlimab, an anti-PD-1 antibody, and additional medicines is being investigated in this open-label, Phase II platform trial. The platform’s Module C is evaluating ezabenlimab plus BI 836880, a humanized bispecific…

Susanna Ulahannan, MD, MMEd, Assistant Professor, Associate Director Phase 1 Unit at University Of Oklahoma Health Sciences Center. In this video, she speaks about the ASCO GI 2022 Abstract – Ezabenlimab (BI 754091), an anti-PD-1 antibody, in combination with BI 836880, a VEGF/Ang2-blocking nanobody, in patients (pts) with advanced colorectal cancer (CRC).   Origins:   Anti-PD-1 antibodies may work in tandem with other immunomodulatory or targeted drugs. The combination of ezabenlimab, an anti-PD-1 antibody, and additional medicines is being investigated in this open-label, Phase II platform trial. The platform’s Module C is evaluating ezabenlimab plus BI 836880, a humanized bispecific…

Prof. Dr. med. Enrico de Toni, Medical Clinic and Polyclinic II at LMU Klinikum der Universität München. In this video, he speaks about the ASCO GI 2022 Abstract – Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: The DEMAND randomized phase II clinical trial.   Origins: The first approved immunotherapeutic regimen for the first-line treatment of patients with advanced hepatocellular carcinoma is atezolizumab with bevacizumab (HCC). The efficacy and tolerability of this regimen suggest that it could be used in combination with transarterial chemoembolization to treat patients with intermediate-stage HCC (TACE). In non-responders to TACE, the combination of TACE…

Prof. Dr. med. Enrico de Toni, Medical Clinic and Polyclinic II at LMU Klinikum der Universität München. In this video, he speaks about the ASCO GI 2022 Abstract – Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: The DEMAND randomized phase II clinical trial.   Origins: The first approved immunotherapeutic regimen for the first-line treatment of patients with advanced hepatocellular carcinoma is atezolizumab with bevacizumab (HCC). The efficacy and tolerability of this regimen suggest that it could be used in combination with transarterial chemoembolization to treat patients with intermediate-stage HCC (TACE). In non-responders to TACE, the combination of TACE…

Augusto Villanueva, MD, Ph.D., Associate Professor, Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai (NY). In this video, he speaks about the ASCO GI 2022 Presentation – Immunotherapy in early-stage hepatocellular carcinoma.

Augusto Villanueva, MD, Ph.D., Associate Professor, Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai (NY). In this video, he speaks about the ASCO GI 2022 Presentation – Immunotherapy in early-stage hepatocellular carcinoma.

William Harris, MD, Associate Professor, Clinical Research Division at Fred Hutchinson Cancer Research Center. In this video, he speaks about the ASCO GI 2022 Abstract – Radioembolization with chemotherapy for liver-dominant colorectal cancer: Analysis of patient subgroups in the EPOCH trial. Origins: In patients with liver-dominant metastatic colorectal illness, the EPOCH study compared the benefits of second-line transarterial radioembolization (TARE) plus chemotherapy to chemotherapy alone (mCRC). Additional EPOCH depth and duration of response (DoR), progression-free survival (PFS), and hepatic progression-free survival (hPFS) subgroup studies are included here. Methodologies: EPOCH was a randomized, open-label, worldwide, multicenter phase 3 trial comparing results…

William Harris, MD, Associate Professor, Clinical Research Division at Fred Hutchinson Cancer Research Center. In this video, he speaks about the ASCO GI 2022 Abstract – Radioembolization with chemotherapy for liver-dominant colorectal cancer: Analysis of patient subgroups in the EPOCH trial. Origins: In patients with liver-dominant metastatic colorectal illness, the EPOCH study compared the benefits of second-line transarterial radioembolization (TARE) plus chemotherapy to chemotherapy alone (mCRC). Additional EPOCH depth and duration of response (DoR), progression-free survival (PFS), and hepatic progression-free survival (hPFS) subgroup studies are included here. Methodologies: EPOCH was a randomized, open-label, worldwide, multicenter phase 3 trial comparing results…

Pashtoon Kasi, MD, MS, Director, Colon Cancer Research, Director, Liquid Biopsy Research, Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, Englander Institute of Precision MedicineClinical Assistant Professor of Internal Medicine – Hematology, Oncology and Blood and Marrow Transplantation from Weill Cornell Medicine and NewYork-Presbyterian Hospital. In this video, he speaks about the ASCO GI 2022 Abstract – Integration of molecular cancer classification and NGS to identify metastatic patients eligible for IDH inhibitors.   Origins: Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) mutations are common in hematologic and solid cancers. Based on enhanced progression-free survival (PFS) and overall…

Pashtoon Kasi, MD, MS, Director, Colon Cancer Research, Director, Liquid Biopsy Research, Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, Englander Institute of Precision MedicineClinical Assistant Professor of Internal Medicine – Hematology, Oncology and Blood and Marrow Transplantation from Weill Cornell Medicine and NewYork-Presbyterian Hospital. In this video, he speaks about the ASCO GI 2022 Abstract – Integration of molecular cancer classification and NGS to identify metastatic patients eligible for IDH inhibitors. Origins: Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) mutations are common in hematologic and solid cancers. Based on enhanced progression-free survival (PFS) and overall survival,…

Ryan Sugarman, MD, Strategic Partnerships Medical Director, Divison of Solid Tumor Oncology, and Assistant Attending of the Gastrointestinal Medical Oncology Service at Memorial Sloan Kettering Cancer Center. In this video, he speaks about the ASCO GI 2022 Abstract – A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of patients in CheckMate 649: Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC). Origins: Patients who received nivolumab with chemotherapy (NIVO + chemo) had better overall survival (OS), progression-free survival (PFS), and maintained their HRQOL for longer in CheckMate 649 (CM 649), a randomized…

CheckMate 649: Long-Term Data Support Nivolumab Plus Chemotherapy but Not Nivolumab Plus Ipilimumab in Gastric Cancer This is a study that is called a Quality-adjusted Time Without Symptoms or toxicity. A Brief Q-TWiST analysis. And we specifically looked at it for the CheckMate 649, which was a study that compared standard of care chemotherapy to chemotherapy plus Nivolumab (Opdivo) in patients previously untreated for gastroesophageal junction and esophageal cancers. The purpose of the study is basically that the prognosis is very poor for gastroesophageal junction cancer. Sadly patients live on average, less than a year prior to this trial, the…

Peter Kim, MD, Associate Professor, Department of Cardiology, Division of Internal Medicine at MD Anderson Cancer Center. In this video, he speaks about Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity.   Abstract:   Immune checkpoint inhibitors (ICIs) have been shown to enhance outcomes in a variety of malignancies, and studies are being conducted to increase their indications and use. Immune-related adverse effects, such as myocarditis, have been identified, with myocarditis being linked to a high mortality rate. Arrhythmias, pericardial illness, and coronary atherosclerosis have all been reported in patients receiving ICI therapy. Increased inflammatory responses after the inactivation of particular checkpoint proteins…

Peter Kim, MD, Associate Professor, Department of Cardiology, Division of Internal Medicine at MD Anderson Cancer Center. In this video, he speaks about Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity. Abstract: Immune checkpoint inhibitors (ICIs) have been shown to enhance outcomes in a variety of malignancies, and studies are being conducted to increase their indications and use. Immune-related adverse effects, such as myocarditis, have been identified, with myocarditis being linked to a high mortality rate. Arrhythmias, pericardial illness, and coronary atherosclerosis have all been reported in patients receiving ICI therapy. Increased inflammatory responses after the inactivation of particular checkpoint proteins on T…

Heinz-Josef Lenz, MD, is a professor in the Departments of Medicine and Preventive Medicine in Keck School of Medicine’s oncology division. He is the associate director of clinical research of the USC Norris Comprehensive Cancer Center, is chair of the GI Oncology Program, and is the co-director of the Colorectal Center. He also serves as the scientific director of the Cancer Genetics Unit. In this video, he speaks about the ASCO GI 2022 Abstract – A phase 1b/2 trial of the PLK1 inhibitor onvansertib in combination with FOLFIRI-bev in 2L treatment of KRAS-mutated (mKRAS) metastatic colorectal carcinoma (mCRC).   Origins:…

Heinz-Josef Lenz, MD, is a professor in the Departments of Medicine and Preventive Medicine in Keck School of Medicine’s oncology division. He is the associate director of clinical research of the USC Norris Comprehensive Cancer Center, is chair of the GI Oncology Program, and is the co-director of the Colorectal Center. He also serves as the scientific director of the Cancer Genetics Unit. In this video, he speaks about the ASCO GI 2022 Abstract – A phase 1b/2 trial of the PLK1 inhibitor onvansertib in combination with FOLFIRI-bev in 2L treatment of KRAS-mutated (mKRAS) metastatic colorectal carcinoma (mCRC).   Origins:…

Pashtoon Kasi, MD, MS, Director, Colon Cancer Research, Director, Liquid Biopsy Research, Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, Englander Institute of Precision MedicineClinical Assistant Professor of Internal Medicine – Hematology, Oncology and Blood and Marrow Transplantation from Weill Cornell Medicine and NewYork-Presbyterian Hospital. In this video, he speaks about the ASCO GI 2022 Abstract – Clinical utility of microsatellite instability (MSI-H) identified on liquid biopsy in advanced gastrointestinal cancers (aGI).     Origins:   Given the approval of many immune checkpoint medications, finding MSI-H in patients with aGI is clinically significant. MSI-H has long been determined…

Pashtoon Kasi, MD, MS, Director, Colon Cancer Research, Director, Liquid Biopsy Research, Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, Englander Institute of Precision MedicineClinical Assistant Professor of Internal Medicine – Hematology, Oncology and Blood and Marrow Transplantation from Weill Cornell Medicine and NewYork-Presbyterian Hospital. In this video, he speaks about the ASCO GI 2022 Abstract – Clinical utility of microsatellite instability (MSI-H) identified on liquid biopsy in advanced gastrointestinal cancers (aGI).     Origins:   Given the approval of many immune checkpoint medications, finding MSI-H in patients with aGI is clinically significant. MSI-H has long been determined…

Rutika Mehta, MD, MPH from Moffits Cancer Center. In this interview, Dr. Mehta speaks about the ASCO GI 2022 Abstract – A phase II study of TAS-102 (FTD/TPI) in combination with ramucirumab (RAM) in advanced, refractory gastric (GC) or gastroesophageal junction (GEJ) adenocarcinomas (GEAs).   Context:   After the failure of fluoropyrimidine and platinum-based chemotherapy, the RAINBOW study established the standard of care for treating metastatic GEAs with ramucirumab and paclitaxel. While the combination had a 28 percent objective response rate (ORR), there was a 46 percent incidence of any grade neuropathy. As a result, there is an unmet need…

Rutika Mehta, MD, MPH, Medical Oncologist in Gastrointestinal Oncology at Moffitt Cancer Center. In this video, she speaks about the ASCO GI 2022 Abstract – A phase II study of TAS-102 (FTD/TPI) in combination with ramucirumab (RAM) in advanced, refractory gastric (GC) or gastroesophageal junction (GEJ) adenocarcinomas (GEAs).   Origins:   After the failure of fluoropyrimidine and platinum-based chemotherapy, the RAINBOW study established the standard of care for treating metastatic GEAs with ramucirumab and paclitaxel. While the combination had a 28 percent objective response rate (ORR), there was a 46 percent incidence of any grade neuropathy. As a result, there…

Shimoli Barot, MD, Hematology/Oncology Fellow at the Cleveland Clinic. In this video, she speaks about the ASCO GI 2022 Abstract – Tumor microbiome variation in young versus average onset colorectal cancer.   Origins:   Young-onset colorectal cancer (yoCRC) is on the rise at an alarming rate. The rise could be due to a change in the gut microbiome. We looked examined the variations in the intratumoral microbiome between young-onset CRC (yoCRC) and average-onset CRC (aoCRC) and their clinical implications.   Methodologies:   Between 2000 and 2020, we identified 314 histologically confirmed cases of stage I-IV CRC that underwent surgical resection…

Shimoli Barot, MD, Hematology/Oncology Fellow at the Cleveland Clinic. In this video, she speaks about the ASCO GI 2022 Abstract – Tumor microbiome variation in young versus average onset colorectal cancer.   Origins:   Young-onset colorectal cancer (yoCRC) is on the rise at an alarming rate. The rise could be due to a change in the gut microbiome. We looked examined the variations in the intratumoral microbiome between young-onset CRC (yoCRC) and average-onset CRC (aoCRC) and their clinical implications.   Methodologies:   Between 2000 and 2020, we identified 314 histologically confirmed cases of stage I-IV CRC that underwent surgical resection…

Thomas George, MD, FACP, Professor, MD-Hematology/Oncology from UF Health Cancer Center. In this video, he speaks about the ASCO GI 2022 Abstract – Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2.     Origins:   Although immunotherapy has not been shown to improve anti-tumor activity in microsatellite stable (MSS) colorectal cancer, preclinical models suggest that radiotherapy (RT) can improve neoantigen presentation, modulate the microenvironment, and increase the likelihood of anti-tumor activity when combined with checkpoint inhibitors. This prospective phase II trial will use a “window-of-opportunity” study design to test the safety and activity of…

Thomas George, MD, FACP, Professor, MD-Hematology/Oncology from UF Health Cancer Center. In this video, he speaks about the ASCO GI 2022 Abstract – Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2.     Origins:   Although immunotherapy has not been shown to improve anti-tumor activity in microsatellite stable (MSS) colorectal cancer, preclinical models suggest that radiotherapy (RT) can improve neoantigen presentation, modulate the microenvironment, and increase the likelihood of anti-tumor activity when combined with checkpoint inhibitors. This prospective phase II trial will use a “window-of-opportunity” study design to test the safety and activity of…

Michael C. Heinrich, FACP, MD, Professor of Medicine, School of Medicine, Cell and Developmental Biology Graduate Program, School of Medicine, Cancer Biology Graduate Program, School of Medicine, Program in Molecular and Cellular Biosciences, School of Medicine from Oregon Health & Science University. In this video he speaks about the ASCO GI 2022 Planetary Series – INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib.   Brief Synopsis:   This is a randomized, open-label, multinational, multicenter trial comparing the efficacy of DCC-2618…

Michael C. Heinrich, FACP, MD, Professor of Medicine, School of Medicine, Cell and Developmental Biology Graduate Program, School of Medicine, Cancer Biology Graduate Program, School of Medicine, Program in Molecular and Cellular Biosciences, School of Medicine from Oregon Health & Science University. In this video he speaks about the ASCO GI 2022 Planetary Series – INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib. Brief Synopsis: This is a randomized, open-label, multinational, multicenter trial comparing the efficacy of DCC-2618 to sunitinib…

Anna Woloszynska, Ph.D., Associate Professor of Oncology in Roswell Park’s Department of Pharmacology and Therapeutics. In this video, she speaks about the article – Received a two-year, $613,000 grant from the U.S. Department of Defense to study the genetic and epigenetic vulnerabilities of prostate cancer in African American men.    BUFFALO, New York — In the United States, African American males have the highest prevalence of prostate cancer and the worst prognosis. Two Roswell Park Comprehensive Cancer Center teams will use new money from the US Department of Defense and the American Cancer Society to study and eliminate prostate cancer…

Anna Woloszynska, Ph.D., Associate Professor of Oncology in Roswell Park’s Department of Pharmacology and Therapeutics. In this video, she speaks about the article – Received a two-year, $613,000 grant from the U.S. Department of Defense to study the genetic and epigenetic vulnerabilities of prostate cancer in African American men.    BUFFALO, New York — In the United States, African American males have the highest prevalence of prostate cancer and the worst prognosis. Two Roswell Park Comprehensive Cancer Center teams will use new money from the US Department of Defense and the American Cancer Society to study and eliminate prostate cancer…

Priyanka A. Pophali, MD, Assistant Professor, Division of Hematology at the University of Wisconsin-Madison. In this video, she speaks about the ASH 2021 Abstract – 1562 Quality of Life in Patients <=70 Years of Age with Chronic Lymphocytic Leukemia Treated Frontline with Ibrutinib-Rituximab Versus Fludarabine Cyclophosphamide Rituximab: Analysis from ECOG-ACRIN E1912. Dr. Pophali co-authored this study with Lynne I Wagner, Ph.D., and others.   Origins: In comparison to previous standard chemo-immunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR), the ECOG-ACRIN randomized phase 3 clinical trial E1912 established ibrutinib-rituximab (IR) as the standard of care for CLL patients 70 years in the…

Priyanka A. Pophali, MD, Assistant Professor, Division of Hematology at the University of Wisconsin-Madison. In this video, she speaks about the ASH 2021 Abstract – 1562 Quality of Life in Patients <=70 Years of Age with Chronic Lymphocytic Leukemia Treated Frontline with Ibrutinib-Rituximab Versus Fludarabine Cyclophosphamide Rituximab: Analysis from ECOG-ACRIN E1912. Dr. Pophali co-authored this study with Lynne I Wagner, Ph.D., and others. Origins: In comparison to previous standard chemo-immunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR), the ECOG-ACRIN randomized phase 3 clinical trial E1912 established ibrutinib-rituximab (IR) as the standard of care for CLL patients 70 years in the frontline…

Heloisa Soares, MD, Ph.D., Associate Professor at Huntsman Cancer Institute. In this video, she speaks about the ASCO GI 2022 Abstract – Randomized phase II trial of postoperative adjuvant capecitabine and temozolomide versus observation in high-risk pancreatic neuroendocrine tumors: SWOG S2104. This study was led by SWOG, and is Co-Chair with Dr. Syed A. Ahmad, University of Cincinnati.   Origins: Resection is the sole curative purpose method for pancreatic neuroendocrine tumors (pNETS), which account for roughly 1-2 percent of all pancreatic tumors; however, many patients will have recurrence after surgery. Recurrence is prognosticated by tumor size, positive lymph nodes, and…

Professor Caio Max S. Rocha Lima, MD, M. Robert Cooper Professor in Medical Oncology, Co-leader GI Oncology and Co-leader Phase I Program, Division of Hematology and Oncology from Wake Forest School of Medicine. In this video he speaks about the ASCO GI 2022 Abstract – NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).   Origins:   Despite the superiority of inhibition of the programmed cell death-1 (PD-1) pathway…

Mustafa Raoof, M.D., M.S., Surgical Oncologist at the City of Hope. In this video, he speaks about the ASCO GI 2022 Abstract – Safety and efficacy of pressurized intraperitoneal aerosolized chemotherapy in appendiceal and colorectal cancer patients with peritoneal carcinomatosis: A first-in-US phase I study.   Origins: The use of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) as a potential minimally invasive palliative treatment for peritoneal metastases is being investigated (PM). Repeated PIPAC treatments in gastrointestinal and gynecologic cancers have been proven to be feasible and safe in previous investigations. The purpose of this phase 1 experiment was to determine the safety…

Katherine Pogue-Geile, Ph.D., Assistant Director of Molecular Profiling at NSABP Foundation. In this video, she speaks about the ASCO GI 2022 Abstract – Multiplex-immunofluorescence (m-IF) and gene expression signature with prognosis and Bevacizumab (bev).   Origins:   In the NRG Oncology/NSABP C-08 study, individuals with stage II or III colon cancer were given bev in addition to mFOLFOX. We discovered that MMR status was predictive of bev benefit in an unplanned analysis, with dMMR pts having statistically significant bev benefit. We recently discovered that immune cells and immunological checkpoint proteins in C-08 mice had varied effects on prognosis and bev…

Samuel J Klempner, MD a gastrointestinal medical oncologist with a clinical and research focus in upper GI cancers, specifically gastroesophageal cancers at Dana-Farber/Harvard Cancer Center. In this video, he speaks about the ASCO GI 2022 Abstract – DKN-01 and tislelizumab ± chemotherapy as a first-line (1L) and second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial.   Origins: Despite the recent approval of anti-PD-1 antibodies as 1L therapy in HER2(-) advanced GEA, the benefit is minimal and limited solely to PD-L1(+) patients (pts), primarily those with CPS 5. As a result, novel therapeutic techniques for this patient population…

Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic. In this video, he discusses the ASCO GI 2022 Abstract – REVERCEII (ACCRU-GI-1809): A randomized phase II study of regorafenib followed by anti-EGFR monoclonal antibody therapy versus the reverse sequencing for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin and irinotecan.   Origins:   Regorafenib (R) is an oral multikinase inhibitor that inhibits several protein kinases involved in angiogenesis and oncogenesis, and it has been shown to improve survival in refractory metastatic colorectal cancer patients (mCRC). In patients (pts) with RAS wildtype (WT) mCRC, the current standard (std) treatment is…

Katherine Pogue-Geile, Ph.D., Assistant Director of Molecular Profiling at NSABP Foundation. In this video, she speaks about the ASCO GI 2022 Abstract – Multiplex-immunofluorescence (m-IF) and gene expression signature with prognosis and Bevacizumab (bev).   Origins: In the NRG Oncology/NSABP C-08 study, individuals with stage II or III colon cancer were given bev in addition to mFOLFOX. We discovered that MMR status was predictive of bev benefit in an unplanned analysis, with dMMR pts having statistically significant bev benefit. We recently discovered that immune cells and immunological checkpoint proteins in C-08 mice had varied effects on prognosis and bev benefit…

Samuel J Klempner, MD a gastrointestinal medical oncologist with a clinical and research focus in upper GI cancers, specifically gastroesophageal cancers at Dana-Farber/Harvard Cancer Center. In this video, he speaks about the ASCO GI 2022 Abstract – DKN-01 and tislelizumab ± chemotherapy as a first-line (1L) and second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial.   Origins: Despite the recent approval of anti-PD-1 antibodies as 1L therapy in HER2(-) advanced GEA, the benefit is minimal and limited solely to PD-L1(+) patients (pts), primarily those with CPS 5. As a result, novel therapeutic techniques for this patient population…

Heloisa Soares, MD, Ph.D., Associate Professor at Huntsman Cancer Institute. In this video, she speaks about the ASCO GI 2022 Abstract – Randomized phase II trial of postoperative adjuvant capecitabine and temozolomide versus observation in high-risk pancreatic neuroendocrine tumors: SWOG S2104. This study was led by SWOG, and is Co-Chair with Dr. Syed A. Ahmad, University of Cincinnati.   Origins:   Resection is the sole curative purpose method for pancreatic neuroendocrine tumors (pNETS), which account for roughly 1-2 percent of all pancreatic tumors; however, many patients will have recurrence after surgery. Recurrence is prognosticated by tumor size, positive lymph nodes,…

Professor Caio Max S. Rocha Lima, MD, M. Robert Cooper Professor in Medical Oncology, Co-leader GI Oncology and Co-leader Phase I Program, Division of Hematology and Oncology from Wake Forest School of Medicine. In this video he speaks about the ASCO GI 2022 Abstract – NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).   Origins:   Despite the superiority of inhibition of the programmed cell death-1 (PD-1) pathway…

Mustafa Raoof, M.D., M.S., Surgical Oncologist at the City of Hope. In this video, he speaks about the ASCO GI 2022 Abstract – Safety and efficacy of pressurized intraperitoneal aerosolized chemotherapy in appendiceal and colorectal cancer patients with peritoneal carcinomatosis: A first-in-US phase I study.   Origins:   The use of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) as a potential minimally invasive palliative treatment for peritoneal metastases is being investigated (PM). Repeated PIPAC treatments in gastrointestinal and gynecologic cancers have been proven to be feasible and safe in previous investigations. The purpose of this phase 1 experiment was to determine the…

Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic. In this video, he discusses the ASCO GI 2022 Abstract – REVERCEII (ACCRU-GI-1809): A randomized phase II study of regorafenib followed by anti-EGFR monoclonal antibody therapy versus the reverse sequencing for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin and irinotecan.   Origins:   Regorafenib (R) is an oral multikinase inhibitor that inhibits several protein kinases involved in angiogenesis and oncogenesis, and it has been shown to improve survival in refractory metastatic colorectal cancer patients (mCRC). In patients (pts) with RAS wildtype (WT) mCRC, the current standard (std) treatment is…

Ghassan Khaled Abou-Alfa, MD, MBA, Medical Oncologist, Attending Physician at Memorial Sloan Kettering Cancer Center. In this video, he speaks about the ASCO GI 2022 Abstract – Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.Origins:In a phase 2 uHCC study (Study 22, NCT02519348), a single priming dose of T (anti-CTLA-4) added to D (anti-PD-L1) in the STRIDE (Single T Regular Interval D) regimen, formerly T300+D, showed encouraging clinical activity and limited toxicity, suggesting that a single exposure to T is sufficient to improve D…

Ghassan Khaled Abou-Alfa, MD, MBA, Medical Oncologist, Attending Physician at Memorial Sloan Kettering Cancer Center. In this video, he speaks about the ASCO GI 2022 Abstract – Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.Origins:In a phase 2 uHCC study (Study 22, NCT02519348), a single priming dose of T (anti-CTLA-4) added to D (anti-PD-L1) in the STRIDE (Single T Regular Interval D) regimen, formerly T300+D, showed encouraging clinical activity and limited toxicity, suggesting that a single exposure to T is sufficient to improve D…

John Strickler, MD, Associate Professor of Medicine, Member of the Duke Cancer Institute at Duke University. In this video, he speaks about the ASCO GI 2022 Discussion – Tailoring Systemic and Local Therapies in Oligometastatic Cancer: A Case-Based Discussion.

Bettzy Stephen, MBBS, MPH, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center. In this interview, she speaks about Immune System in Action.Abstract:Tumors are made up of a complex network of structures that can evolve and evade the host’s immune system. In the core, the invasive margin, or the surrounding stromal or lymphoid component of the tumor, macrophages, dendritic cells, natural killer cells, neutrophils, mast cells, B cells, and T cells are detected. The immune infiltration is diverse, varying both within and between patients with the same histology of tumor. The nature of the immune response,…

Bettzy Stephen, MBBS, MPH, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center. In this interview, she speaks about Immune System in Action.Abstract:Tumors are made up of a complex network of structures that can evolve and evade the host ‘s immune system. In the core, the invasive margin, or the surrounding stromal or lymphoid component of the tumor, macrophages, dendritic cells, natural killer cells, neutrophils, mast cells, B cells, and T cells are detected. The immune infiltration is diverse, varying both within and between patients with the same histology of tumor. The nature of the immune…

Jeremy Sharib, MD, Complex General Surgical Oncology Fellow at Duke University. In this interview, he speaks about ASCO GI 2022 Abstract – Perioperative and oncologic outcomes of hepatic artery infusion pump therapy at an expanding HAI program.Origins:Unresectable or resected colorectal liver metastases (CRLM) and unresectable intrahepatic cholangiocarcinoma are treated with hepatic artery infusion (HAI) (ICC). Historically, HAI was only performed at a few specialist sites; now, the number of new centers is growing. We recently discussed the safety results of our first year of HAI therapy. We now have results for an enlarged cohort of 62 patients in an established…

Jeremy Sharib, MD, Complex General Surgical Oncology Fellow at Duke University. In this interview, he speaks about ASCO GI 2022 Abstract – Perioperative and oncologic outcomes of hepatic artery infusion pump therapy at an expanding HAI program.Origins:Unresectable or resected colorectal liver metastases (CRLM) and unresectable intrahepatic cholangiocarcinoma are treated with hepatic artery infusion (HAI) (ICC). Historically, HAI was only performed at a few specialist sites; now, the number of new centers is growing. We recently discussed the safety results of our first year of HAI therapy. We now have results for an enlarged cohort of 62 patients in an established…

Rachna T. Shroff, MD, Associate Dean, Clinical and Translational Research, Associate Professor, Medicine – (Clinical Scholar Track), Chief, Section of GI Medical Oncology, UA Cancer Center, Leader, GI Clinical Research Team, UArizona Cancer Center, Director, UArizona Cancer Center Clinical Trials Office at the University of Arizona. In this interview, she speaks about Broadening Access to Cancer Drugs: The Right Trials for the Right Patients?

Rachna T. Shroff, MD, Associate Dean, Clinical and Translational Research, Associate Professor, Medicine – (Clinical Scholar Track), Chief, Section of GI Medical Oncology, UA Cancer Center, Leader, GI Clinical Research Team, UArizona Cancer Center, Director, UArizona Cancer Center Clinical Trials Office at the University of Arizona. In this interview, she speaks about Broadening Access to Cancer Drugs: The Right Trials for the Right Patients?

Al Benson III, MD, Professor, Medicine, Hematology-Oncology Division; Feinberg School of Medicine at Northwestern University. In this video he speaks about the ASCO GI 2022 Abstract – A phase II study of FOLFOX combined with nab-paclitaxel (FOLFOX-A) in the treatment of metastatic or advanced unresectable gastric, gastroesophageal junction adenocarcinoma: Big Ten Cancer Research Consortium—BTCRC-GI15-015.Origins:The current standard of care for advanced gastric/GEJ cancer is doublet platinum or taxane-based treatments. Anthracycline-based triplets had already been abandoned due to a lack of efficacy and toxicity. We believe that combining FOLFOX with nab-paclitaxel (FOLFOX-A) will result in improved effectiveness, tolerability, and patient reported outcomes.Methodologies:In…

Al Benson III, MD, Professor, Medicine, Hematology-Oncology Division; Feinberg School of Medicine at Northwestern University. In this video he speaks about the ASCO GI 2022 Abstract – A phase II study of FOLFOX combined with nab-paclitaxel (FOLFOX-A) in the treatment of metastatic or advanced unresectable gastric, gastroesophageal junction adenocarcinoma: Big Ten Cancer Research Consortium—BTCRC-GI15-015.Origins:The current standard of care for advanced gastric/GEJ cancer is doublet platinum or taxane-based treatments. Anthracycline-based triplets had already been abandoned due to a lack of efficacy and toxicity. We believe that combining FOLFOX with nab-paclitaxel (FOLFOX-A) will result in improved effectiveness, tolerability, and patient reported outcomes.Methodologies:In…

Erica K. Barnell, MD, Ph.D. Chief Science Officer at Geneoscopy. In this interview, she speaks about CRC-PREVENT: Clinical validation trial to show expedited and diverse recruitment for the non-invasive RNA-FIT test that can detect advanced colorectal neoplasia with high sensitivity.Origins:In large prospective studies, standard patient recruiting procedures can be time-consuming, costly, and introduce selection bias against patients with low health literacy or limited access to healthcare. Women, minorities, and those with low income have been underrepresented in previous clinical trials, a problem that has been compounded by the COVID-19 epidemic. We describe an innovative recruitment technique that aids in the…

Erica K. Barnell, MD, Ph.D. Chief Science Officer at Geneoscopy. In this interview, she speaks about CRC-PREVENT: Clinical validation trial to show expedited and diverse recruitment for the non-invasive RNA-FIT test that can detect advanced colorectal neoplasia with high sensitivity.Origins:In large prospective studies, standard patient recruiting procedures can be time-consuming, costly, and introduce selection bias against patients with low health literacy or limited access to healthcare. Women, minorities, and those with low income have been underrepresented in previous clinical trials, a problem that has been compounded by the COVID-19 epidemic. We describe an innovative recruitment technique that aids in the…

Afsaneh Barzi, MD, Ph.D., Director, Employer Strategy (AccessHope); Associate Professor, Department of Medical Oncology &amp; Therapeutics Research at the City of Hope. In this video, she speaks about the ASCO GI 2022 Abstract – Phase I/II study of regorafenib (rego) and pembrolizumab (pembro) in refractory microsatellite stable colorectal cancer (MSSCRC). History:In MSSCRC, immune checkpoint inhibitors (ICI) are ineffective. The use of ICI in combination with targeted therapies has the potential to change the tumor microenvironment and make these malignancies more sensitive to ICI. The results of a multicenter rego and pembro study in a varied patient population with advanced MSSCRC…

Afsaneh Barzi, MD, Ph.D., Director, Employer Strategy (AccessHope); Associate Professor, Department of Medical Oncology &amp; Therapeutics Research at the City of Hope. In this video, she speaks about the ASCO GI 2022 Abstract – Phase I/II study of regorafenib (rego) and pembrolizumab (pembro) in refractory microsatellite stable colorectal cancer (MSSCRC). History:In MSSCRC, immune checkpoint inhibitors (ICI) are ineffective. The use of ICI in combination with targeted therapies has the potential to change the tumor microenvironment and make these malignancies more sensitive to ICI. The results of a multicenter rego and pembro study in a varied patient population with advanced MSSCRC…

Erqi Pollom, MD, Assistant Professor of Radiation Oncology and, by courtesy, of Neurosurgery at Stanford Hospital and ClinicsLucile Packard Children’s Hospital, and University HealthCare Alliance. In this video she speaks about the ASCO GI 2022 Abstract – Phase II trial of organ preservation program using short-course radiation and folfoxiri for rectal cancer (SHORT-FOX). This study was conducted along with George A. Fisher Jr., MD, Daniel Chang, MD, Andy Johnson, MD, and others.Brief history:Preoperative chemoradiotherapy and total mesorectal excision are used to treat locally advanced rectal cancer (TME). While this trimodal method results in modest local recurrence rates, distant metastatic rates…

Erqi Pollom, MD, Assistant Professor of Radiation Oncology and, by courtesy, of Neurosurgery at Stanford Hospital and Clinics, Lucile Packard Children’s Hospital, and University HealthCare Alliance. In this video she speaks about the ASCO GI 2022 Abstract – Phase II trial of organ preservation program using short-course radiation and folfoxiri for rectal cancer (SHORT-FOX). This study was conducted along with George A. Fisher Jr., MD, Daniel Chang, MD, Andy Johnson, MD, and others.Brief history:Preoperative chemoradiotherapy and total mesorectal excision are used to treat locally advanced rectal cancer (TME). While this trimodal method results in modest local recurrence rates, distant metastatic…

Angela DeMichele, MD, MSCE, Co-Leader, Breast Cancer Research Program, Director, Breast Cancer Clinical Trials Unit, Co-Director, 2-PREVENT Breast Cancer Translational Center of Excellence, Alan and Jill Miller Professor in Breast Cancer Excellence from Penn Medicine and PennMedicine’s Abramson Cancer Center. In this video, she speaks about the SABCS 2021 Abstract – GS1-07 Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial.

Angela DeMichele, MD, MSCE, Co-Leader, Breast Cancer Research Program, Director, Breast Cancer Clinical Trials Unit, Co-Director, 2-PREVENT Breast Cancer Translational Center of Excellence, Alan and Jill Miller Professor in Breast Cancer Excellence from Penn Medicine and PennMedicine’s Abramson Cancer Center. In this video, she speaks about the SABCS 2021 Abstract – GS1-07 Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial.

Dhyan Chandra, Ph.D., Associate Professor of Oncology, Department of Pharmacology & Therapeutics at Roswell Park Cancer Center. In this video, he discusses the article – Received a two-year, $240,000 grant from the American Cancer Society to study cytochrome c deficiency in African American men.   BUFFALO, New York — In the United States, African American males have the highest prevalence of prostate cancer and the worst prognosis. Two Roswell Park Comprehensive Cancer Center teams will use new money from the US Department of Defense and the American Cancer Society to study and eliminate prostate cancer health disparities.   African American…

Dhyan Chandra, Ph.D., Associate Professor of Oncology, Department of Pharmacology & Therapeutics at Roswell Park Cancer Center. In this video, he discusses the article – Received a two-year, $240,000 grant from the American Cancer Society to study cytochrome c deficiency in African American men.   BUFFALO, New York — In the United States, African American males have the highest prevalence of prostate cancer and the worst prognosis. Two Roswell Park Comprehensive Cancer Center teams will use new money from the US Department of Defense and the American Cancer Society to study and eliminate prostate cancer health disparities.   African American…

Dr. Anwaar Saeed, MD, Associate Professor of Medicine, Division of Medical Oncology, Associate Director- Early Phase Program at University of Kansas Medical Center. In this video, she speaks about the ASCO GI 2022 Abstract CA209-8YD: A phase I/II trial of rucaparib in combination with ramucirumab with or without nivolumab in previously treated advanced gastroesophageal adenocarcinoma (GEA) (RiME). Origins:   Globally and in the United States, GEA is one of the main causes of cancer-related mortality. Therapeutic options for chemo-refractory GEA are limited, and effectiveness is low. PARP inhibitors have been shown to induce synthetic lethality and reduce tumor burden in in…

Dr. Anwaar Saeed, MD, Associate Professor of Medicine, Division of Medical Oncology, Associate Director- Early Phase Program at University of Kansas Medical Center. In this video, she speaks about the ASCO GI 2022 Abstract CA209-8YD: A phase I/II trial of rucaparib in combination with ramucirumab with or without nivolumab in previously treated advanced gastroesophageal adenocarcinoma (GEA) (RiME). Origins:   Globally and in the United States, GEA is one of the main causes of cancer-related mortality. Therapeutic options for chemo-refractory GEA are limited, and effectiveness is low. PARP inhibitors have been shown to induce synthetic lethality and reduce tumor burden in…

Dr. Anwaar Saeed, MD, Associate Professor of Medicine, Division of Medical Oncology, Associate Director- Early Phase Program at University of Kansas Medical Center. In this video, she speaks about the ASCO GI 2022 Abstract – Phase II trial of cabozantinib (Cabo) plus durvalumab (Durva) in chemotherapy refractory patients with advanced mismatch repair proficient/microsatellite stable (pMMR/MSS) colorectal cancer (CRC): CAMILLA CRC cohort results. Origins:   Cabo is a multi-kinase inhibitory anti-VEGFR2/MET/AXL medication with a broad anti-VEGFR2/MET/AXL range. Cabo showed good immune modulatory action in preclinical and clinical tests in several solid malignancies, with clinical synergy evident when paired with PD-1/PD-L1 inhibitors…

Dr. Anwaar Saeed, MD, Associate Professor of Medicine, Division of Medical Oncology, Associate Director- Early Phase Program at University of Kansas Medical Center. In this video, she speaks about the ASCO GI 2022 Abstract – Phase II trial of cabozantinib (Cabo) plus durvalumab (Durva) in chemotherapy refractory patients with advanced mismatch repair proficient/microsatellite stable (pMMR/MSS) colorectal cancer (CRC): CAMILLA CRC cohort results. Origins:   Cabo is a multi-kinase inhibitory anti-VEGFR2/MET/AXL medication with a broad anti-VEGFR2/MET/AXL range. Cabo showed good immune modulatory action in preclinical and clinical tests in several solid malignancies, with clinical synergy evident when paired with PD-1/PD-L1 inhibitors…

John Strickler, MD, Associate Professor of Medicine, Member of the Duke Cancer Institute at Duke University. In this video, he speaks about the ASCO GI 2022 Discussion – Tailoring Systemic and Local Therapies in Oligometastatic Cancer: A Case-Based Discussion.  

Orphan Drug Designation Update: IDEAYA Biosciences inc Darovasertib and Crizotinib Synthetic Lethal Combination Expansion Dose in Heavily Pre-Treated Metastatic Uveal Melanoma (MUM) * Press Release Update May 12, 2022 – IDE196 Darovasertib and crizotinib combination Orphan Drug Designation by FDA Darovasertib has been identified as an Orphan Drug Designation by the U.S. FDA, entitling IDEAYA to certain tax credits, exemption from user fees, and potential statutory marketing exclusivity. -  Targeting a clinical data update for darovasertib and crizotinib combination and FDA regulatory guidance for a potential registration-enabling trial design in mid-2022 SOUTH SAN FRANCISCO, Calif., May 2, 2022 /PRNewswire/ – IDEAYA…

Meredith McKean, MD, Sarah Cannon Research Institute at Tennessee Oncology, Associate Director, Melanoma and Skin Cancer Research speaks about IDEAYA Reports Clinical Data from Phase 2 Expansion Dose of Darovasertib and Crizotinib Synthetic Lethal Combination in Heavily Pre-Treated Metastatic Uveal Melanoma.IDEAYA Biosciences, Inc., a precision medicine oncology company focused on the discovery and development of targeted therapeutics, has provided a clinical data update for the Phase 1/2 trial evaluating the synthetic lethal combination of darovasertib and crizotinib in patients with metastatic uveal melanoma (MUM).There are presently no FDA-approved medicines for metastatic uveal melanoma or GNAQ/GNA11 solid tumors, indicating that there…

Professor Eric Van Cutsem, MD, Ph.D., is full professor and Division Head of Digestive Oncology at the University of Leuven (KUL) and University Hospitals Gasthuisberg, Leuven, Belgium. In this interview, Professor Van Cutsem speaks about Comments on the DESTINY-Gastric02 trial from Enhertu.Brief Synopsis:Participants with stomach or gastroesophageal junction cancer will be enrolled in this trial to see if trastuzumab deruxtecan is safe and effective.They must have stomach or gastro-esophageal junction (GEJ) cancer that is human epidermal growth factor receptor 2 (HER2) positive:* that cannot be surgically removed* that has spread throughout the body* that deteriorated during or during trastuzumab treatmentA…

The DESTINY-Gastric02 study is a very important study because it’s the first study in western patients with HER2 positive Gastric or Gastroesophageal junction adenomas who were progressive on trastuzumab containing chemotherapy. And then, the patients were treated with the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (Enhurtu). This was a study Western in patients and it’s following the Gastric01 study, which was in Asian and Korean patients. This Gastric02 study was a phase two study. It’s a nonrandomized study and the primary endpoint. Is response rate objective response rate as evaluated by independent committee responses are important in this situation because this is…

Yelena Y. Janjigian, MD, Cheif, Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center. In this interview Dr. Janjigian speaks about the ASCO GI 2022 Abstract – Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.Origins:T-DXd is a humanized anti-HER2 monoclonal antibody with a tetrapeptide-based cleavable linker and a topoisomerase I inhibitor payload in an antibody-drug combination. T-DXd is approved in the United States and Israel for HER2+ advanced/metastatic GC/GEJA after a trastuzumab-based treatment, as well as GC after chemotherapy (Japan). In DESTINY-Gastric01, T-DXd outperformed…

Yelena Y. Janjigian, MD, Cheif, Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center. In this interview Dr. Janjigian speaks about the ASCO GI 2022 Abstract – Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.Origins:T-DXd is a humanized anti-HER2 monoclonal antibody with a tetrapeptide-based cleavable linker and a topoisomerase I inhibitor payload in an antibody-drug combination. T-DXd is approved in the United States and Israel for HER2+ advanced/metastatic GC/GEJA after a trastuzumab-based treatment, as well as GC after chemotherapy (Japan). In DESTINY-Gastric01, T-DXd outperformed…

Dr. Michael Mauro, leader of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center. In this video, he speaks about Patients With Chronic-Phase CML Achieved Deeper, More Durable Molecular Responses With Asciminib Vs Bosutinib.According to updated findings from the phase 3 ASCEMBL trial (NCT03106779) presented at the American Society of Hematology Annual Meeting &amp; Exposition, chronic-phase chronic myeloid leukemia (CP-CML) treated with asciminib (Scemblix) was more likely to achieve major molecular response (MMR) than bosutinib (Bosulif) without any new or worsening adverse effects (AEs).The MMR rate at 48 weeks was 29.3 percent with asciminib vs 13.2 percent with bosutinib,…

Dr. Michael Mauro, leader of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center. In this video, he speaks about Patients With Chronic-Phase CML Achieved Deeper, More Durable Molecular Responses With Asciminib Vs Bosutinib.According to updated findings from the phase 3 ASCEMBL trial (NCT03106779) presented at the American Society of Hematology Annual Meeting &amp; Exposition, chronic-phase chronic myeloid leukemia (CP-CML) treated with asciminib (Scemblix) was more likely to achieve major molecular response (MMR) than bosutinib (Bosulif) without any new or worsening adverse effects (AEs).The MMR rate at 48 weeks was 29.3 percent with asciminib vs 13.2 percent with bosutinib,…

Dr. Kohei Shitara is a Chief of Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa in Japan. In this interview, he speaks about the ASCO GI 2022 Abstract – Exploratory analysis of the impact of prior immune checkpoint inhibitor (ICI) on trastuzumab deruxtecan (T-DXd; DS-8201) clinical outcomes and biomarkers (BM) in DESTINY-Gastric01 (DG-01), a randomized, phase 2, multicenter, open-label study in patients (pts) with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma.Context:T-DXd is an antibody-drug combination that targets HER2. T-DXd showed clinically meaningful improvements in objective response rate (ORR) and overall survival (OS) compared to chemotherapy in the primary…

Dr. Kohei Shitara is a Chief of Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa in Japan. In this interview, he speaks about the ASCO GI 2022 Abstract – Exploratory analysis of the impact of prior immune checkpoint inhibitor (ICI) on trastuzumab deruxtecan (T-DXd; DS-8201) clinical outcomes and biomarkers (BM) in DESTINY-Gastric01 (DG-01), a randomized, phase 2, multicenter, open-label study in patients (pts) with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma.Context:T-DXd is an antibody-drug combination that targets HER2. T-DXd showed clinically meaningful improvements in objective response rate (ORR) and overall survival (OS) compared to chemotherapy in the primary…

Richard Francis Dunne, MD, Assistant Professor – Department of Medicine, Hematology/Oncology (SMD) at the University of Rochester Medical Center. In this interview, he speaks about the ASCO GI 2022 Abstract Induction FOLFOX prior to CROSS chemoradiotherapy and surgery in patients with locally-advanced esophageal and gastroesophageal junction cancer: A phase II study.Origins:In the CROSS study, it was discovered that neoadjuvant chemoradiotherapy (CRT) is given before surgery to patients with esophageal (E) and gastroesophageal junction (GEJ) malignancies improved survival. However, 10-year data did not suggest that minimizing isolated distant metastases was beneficial. Prior to CRT, adding full-dose induction chemotherapy (CT) could give…

Richard Francis Dunne, MD, Assistant Professor – Department of Medicine, Hematology/Oncology (SMD) at the University of Rochester Medical Center. In this interview, he speaks about the ASCO GI 2022 Abstract Induction FOLFOX prior to CROSS chemoradiotherapy and surgery in patients with locally-advanced esophageal and gastroesophageal junction cancer: A phase II study.Origins:In the CROSS study, it was discovered that neoadjuvant chemoradiotherapy (CRT) is given before surgery to patients with esophageal (E) and gastroesophageal junction (GEJ) malignancies improved survival. However, 10-year data did not suggest that minimizing isolated distant metastases was beneficial. Prior to CRT, adding full-dose induction chemotherapy (CT) could give…

Dr. Timothy Schmidt from the Carbone Cancer Center, and the University of Wisconsin, is a faculty member of the Division of Hematology, Medical Oncology, and Palliative Care within the Department of Medicine. He is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the International Myeloma Society. Dr. Schmidt also serves as a peer reviewer for clinical hematology journals and is involved in medical education for trainees, medical professionals, and patient outreach organizations. In this video Dr. Schmidt speaks about the ASH 2021 Abstract – 467 Impact of Chromosome 1 Abnormalities Among Patients with…

Dr. Timothy Schmidt from the Carbone Cancer Center, and the University of Wisconsin, is a faculty member of the Division of Hematology, Medical Oncology, and Palliative Care within the Department of Medicine. He is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the International Myeloma Society. Dr. Schmidt also serves as a peer reviewer for clinical hematology journals and is involved in medical education for trainees, medical professionals, and patient outreach organizations. In this video Dr. Schmidt speaks about the ASH 2021 Abstract – 467 Impact of Chromosome 1 Abnormalities Among Patients with…

Daniel Herranz, PharmD, Ph.D., Assistant Professor in the Department of Pharmacology at the Robert Wood Johnson Medical School &amp; Resident Member at Rutgers Cancer Institute of New Jersey speaks about the ASH 2021 Abstract 2221 Sirt1 Is a Novel Therapeutic Target in T-ALL.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper153950.htmlT-cell Acute Lymphoblastic Leukemia (T-ALL) is leukemia that affects both children and adults. Despite this, 20 percent to 50 percent of individuals develop initial resistance or relapse after treatment and eventually succumb to their illness. Because more than 60% of T-ALL individuals have to activate mutations in the NOTCH1 gene, abnormal NOTCH1 signaling plays a key…

Daniel Herranz, PharmD, Ph.D., Assistant Professor in the Department of Pharmacology at the Robert Wood Johnson Medical School &amp; Resident Member at Rutgers Cancer Institute of New Jersey speaks about the ASH 2021 Abstract 2221 Sirt1 Is a Novel Therapeutic Target in T-ALL.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper153950.htmlT-cell Acute Lymphoblastic Leukemia (T-ALL) is leukemia that affects both children and adults. Despite this, 20 percent to 50 percent of individuals develop initial resistance or relapse after treatment and eventually succumb to their illness. Because more than 60% of T-ALL individuals have to activate mutations in the NOTCH1 gene, abnormal NOTCH1 signaling plays a key…

The discussion was on Tuesday, December 7, 2021Optimizing Immunotherapy in Triple-Negative Breast Cancer: Novel Predictive Biomarkers and Blood-Basted Efficacy MonitoringSpeaker -Hope Rugo, MDSpeaks about Challenges and Opportunities for Optimizing Immunotherapies for TNBC

The discussion was on Tuesday, December 7, 2021Optimizing Immunotherapy in Triple-Negative Breast Cancer: Novel Predictive Biomarkers and Blood-Basted Efficacy MonitoringSpeaker -Adam Brufsky, MD, Ph.D.Speaks about Navigating Treatment Decision Points in Management of TNBC: Interactive Case Studies

The discussion was on Tuesday, December 7, 2021Optimizing Immunotherapy in Triple-Negative Breast Cancer: Novel Predictive Biomarkers and Blood-Basted Efficacy MonitoringSpeakers -Adam Brufsky, MD, Ph.D. – Interactive Case StudiesSpeaks about Navigating Treatment Decision Points in Management of TNBC: Interactive Case StudiesGiampaolo Bianchini, MDSpeaks about Harnessing the TNBC Microenvironment to Integrate Novel Predictive BiomarkersHope Rugo, MDSpeaks about Callenges and Oppotrunites for Optimizing Immunotherapies for TNBC

The discussion was on Tuesday, December 7, 2021Optimizing Immunotherapy in Triple-Negative Breast Cancer: Novel Predictive Biomarkers and Blood-Basted Efficacy MonitoringSpeakers -Adam Brufsky, MD, Ph.D. – Interactive Case StudiesSpeaks about Navigating Treatment Decision Points in Management of TNBC: Interactive Case StudiesGiampaolo Bianchini, MDSpeaks about Harnessing the TNBC Microenvironment to Integrate Novel Predictive BiomarkersHope Rugo, MDSpeaks about Callenges and Oppotrunites for Optimizing Immunotherapies for TNBC

The discussion was on Tuesday, December 7, 2021Optimizing Immunotherapy in Triple-Negative Breast Cancer: Novel Predictive Biomarkers and Blood-Basted Efficacy MonitoringSpeaker -Giampaolo Bianchini, MDSpeaks about Harnessing the TNBC Microenvironment to Integrate Novel Predictive Biomarkers

The discussion was on Tuesday, December 7, 2021Optimizing Immunotherapy in Triple-Negative Breast Cancer: Novel Predictive Biomarkers and Blood-Basted Efficacy Monitoring Speakers -Adam Brufsky, MD, PhDSpeaks about Navigating Treatment Decision Points in Management of TNBC: Interactive Case StudiesGiampaolo Bianchini, MDSpeaks about Harnessing the TNBC Microenvironment to Integrate Novel Predictive BiomarkersHope Rugo, MDSpeaks about Callenges and Opportunities for Optimizing Immunotherapies for TNBC

Peter Cole, MD, Rutgers Cancer Institute of New Jersey Embrace Kids Foundation Endowed Chair in Pediatric Hematology/Oncology and Chief of the Division of Pediatric Hematology/Oncology, also affiliated with Robert Wood Johnson University Hospital speaks about the ASH 2021 Abstract – 3485 Performance of Next Generation Sequencing for Minimal Residual Disease Detection for Pediatric Patients with Acute Lymphoblastic Leukemia: Results from the Prospective Clinical Trial DFCI 16-001.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper152369.htmlOverview:In juvenile acute lymphoblastic leukemia, a sensitive and early assessment of minimal residual disease (MRD) is critical for risk classification (ALL). To detect MRD at the level of 1 leukemic cell in a…

Peter Cole, MD, Rutgers Cancer Institute of New Jersey Embrace Kids Foundation Endowed Chair in Pediatric Hematology/Oncology and Chief of the Division of Pediatric Hematology/Oncology, also affiliated with Robert Wood Johnson University Hospital speaks about the ASH 2021 Abstract – 3485 Performance of Next Generation Sequencing for Minimal Residual Disease Detection for Pediatric Patients with Acute Lymphoblastic Leukemia: Results from the Prospective Clinical Trial DFCI 16-001.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper152369.htmlOverview:In juvenile acute lymphoblastic leukemia, a sensitive and early assessment of minimal residual disease (MRD) is critical for risk classification (ALL). To detect MRD at the level of 1 leukemic cell in a…

Philippe Moreau, MD, is Head of the Hematology Department at the University Hospital of Nantes, France speaks about the ASH 2021 Abstract 896 Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper147915.htmlIntroduction:Teclistamab (JNJ-64007957) is a bispecific IgG4 T-cell redirection antibody that binds both BCMA and CD3 receptors to induce T-cell mediated cytotoxicity of BCMA-expressing myeloma cells. MajesTEC-1, an ongoing phase 1/2 research in patients with extensively pretreated relapsed/refractory multiple myeloma, is testing teclistamab (RRMM). After a median of 6.1 months of follow-up, results from the phase…

Philippe Moreau, MD, is Head of the Hematology Department at the University Hospital of Nantes, France speaks about the ASH 2021 Abstract 896 Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper147915.htmlIntroduction:Teclistamab (JNJ-64007957) is a bispecific IgG4 T-cell redirection antibody that binds both BCMA and CD3 receptors to induce T-cell mediated cytotoxicity of BCMA-expressing myeloma cells. MajesTEC-1, an ongoing phase 1/2 research in patients with extensively pretreated relapsed/refractory multiple myeloma, is testing teclistamab (RRMM). After a median of 6.1 months of follow-up, results from the phase…

Adam M. Brufsky, MD, Ph.D., Professor of Medicine, Associate Chief, Division of Hematology/Oncology, Co-Director, Comprehensive Breast Cancer Center, Associate Director, Clinical Investigation at Magee-Womens Cancer Program, part of the UPMC Hillman Cancer Center of Medicine speaks about the Phase III DetermaIOâ„¢ Study.Description in detail:Mononuclear cells and lymphocytes have been found in numerous triple negative and basal-like breast tumors, according to new research. Regardless of the kind of tumor invasion by mononuclear cells, immune regulatory checkpoints like PD-1 and its ligand B7-H1 (or PD-L1) have a deleterious impact on treatment outcomes. These findings imply that PD-L1 expression is an adaptive strategy…

Adam M. Brufsky, MD, Ph.D., Professor of Medicine, Associate Chief, Division of Hematology/Oncology, Co-Director, Comprehensive Breast Cancer Center, Associate Director, Clinical Investigation at Magee-Womens Cancer Program, part of the UPMC Hillman Cancer Center of Medicine speaks about the Phase III DetermaIOâ„¢ Study.Description in detail:Mononuclear cells and lymphocytes have been found in numerous triple negative and basal-like breast tumors, according to new research. Regardless of the kind of tumor invasion by mononuclear cells, immune regulatory checkpoints like PD-1 and its ligand B7-H1 (or PD-L1) have a deleterious impact on treatment outcomes. These findings imply that PD-L1 expression is an adaptive strategy…

Alexis Combes, Ph.D., Director of Disease to Biology Colab at UCSF, Assistant professor department of pathology speaks about Sorting Cancers by “Immune Archetypes” Represents Potential New Approach to Developing Precision Immunotherapies.Link to Article:https://medicalxpress.com/news/2022-01-cancers-immune-archetypes-potential-approach.htmlLink to Study:https://authors.elsevier.com/c/1eJiWL7PXf0ZuSynopsisCancers differ significantly in terms of origin tissue, driver mutations, and other aspects of the surrounding tissue. Individual tumors are likely to engage common immune system patterns, or “archetypes,” to create prototype non-destructive tumor immune microenvironments (TMEs) and modulate tumor-targeting. The Immunoprofiler Initiative (IPI) at the University of California, San Francisco (UCSF) evaluated 364 unique tumors across 12 cancer types using standardized techniques to discover the…

Alexis Combes, Ph.D., Director of Disease to Biology Colab at UCSF, Assistant professor department of pathology speaks about Sorting Cancers by “Immune Archetypes” Represents Potential New Approach to Developing Precision Immunotherapies.Link to Article:https://medicalxpress.com/news/2022-01-cancers-immune-archetypes-potential-approach.htmlLink to Study:https://authors.elsevier.com/c/1eJiWL7PXf0ZuSynopsisCancers differ significantly in terms of origin tissue, driver mutations, and other aspects of the surrounding tissue. Individual tumors are likely to engage common immune system patterns, or “archetypes,” to create prototype non-destructive tumor immune microenvironments (TMEs) and modulate tumor-targeting. The Immunoprofiler Initiative (IPI) at the University of California, San Francisco (UCSF) evaluated 364 unique tumors across 12 cancer types using standardized techniques to discover the…

Brad S. Kahl, MD, Professor of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis speaks about the ASH 2021 Abstract 815 Long Term Follow up of the Resort Study (E4402): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma. Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper152976.htmlContext:E4402 was a randomized phase III trial that compared two alternative rituximab dosing techniques for individuals with low tumor burden follicular lymphoma who had previously been untreated (FL). The time to treatment failure was the primary outcome. The first study (Kahl, JCO 2014) found that a retreatment…

Brad S. Kahl, MD, Professor of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis speaks about the ASH 2021 Abstract 815 Long Term Follow up of the Resort Study (E4402): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma. Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper152976.htmlContext:E4402 was a randomized phase III trial that compared two alternative rituximab dosing techniques for individuals with low tumor burden follicular lymphoma who had previously been untreated (FL). The time to treatment failure was the primary outcome. The first study (Kahl, JCO 2014) found that a retreatment…

Yishai Ofran, MD, Director of Hematology department and Shaare Zedek Medical Center Jerusalem speaks about the ASH 2021 Abstract – 413 Allogeneic Transplantation in Fit Older Adults Is Feasible and Encouragingly Efficacious. Post Remission Data from the Prospective ECOG-ACRIN (E2906) Clinical Study.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper149356.htmlIntroduction:The most effective anti-leukemia treatment after remission is allogeneic stem cell transplantation (alloSCT). However, the accompanying toxicity is a deterrent to its widespread use as standard of care in the elderly. Because randomized controlled trials comparing transplantation to non-transplantation are difficult to conduct, most studies of AML patients who had alloSCT are retrospective. The results of E2906,…

Yishai Ofran, MD, Director of Hematology department and Shaare Zedek Medical Center Jerusalem speaks about the ASH 2021 Abstract – 413 Allogeneic Transplantation in Fit Older Adults Is Feasible and Encouragingly Efficacious. Post Remission Data from the Prospective ECOG-ACRIN (E2906) Clinical Study.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper149356.htmlIntroduction:The most effective anti-leukemia treatment after remission is allogeneic stem cell transplantation (alloSCT). However, the accompanying toxicity is a deterrent to its widespread use as standard of care in the elderly. Because randomized controlled trials comparing transplantation to non-transplantation are difficult to conduct, most studies of AML patients who had alloSCT are retrospective. The results of E2906,…

Marco Ruella, MD, Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies and Scientific Director of the Lymphoma Program at the Hospital of the University of Pennsylvania speaks about the ASH 2021 Abstract 163 Gut Microbiota Tuning Promotes Tumor-Associated Antigen Cross Presentation and Enhances CAR T Antitumor Effects and 253 The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies.Link to Abstract 163:https://ash.confex.com/ash/2021/webprogram/Paper151093.htmlLink to Clinical Trial:https://clinicaltrials.gov/ct2/show/NCT02030847Link to Abstract 253:https://ash.confex.com/ash/2021/webprogram/Paper153945.html

Marco Ruella, MD, Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies and Scientific Director of the Lymphoma Program at the Hospital of the University of Pennsylvania speaks about the ASH 2021 Abstract 163 Gut Microbiota Tuning Promotes Tumor-Associated Antigen Cross Presentation and Enhances CAR T Antitumor Effects and 253 The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies.Link to Abstract 163:https://ash.confex.com/ash/2021/webprogram/Paper151093.htmlLink to Clinical Trial:https://clinicaltrials.gov/ct2/show/NCT02030847Link to Abstract 253:https://ash.confex.com/ash/2021/webprogram/Paper153945.html

J. Joseph Melenhorst, Ph.D., Research Professor of Pathology and Laboratory Medicine Department: Pathology and Laboratory Medicine from the University of Pennsylvania speaks about the ASH 2021 Abstract 166 Decade-Long Remissions of Leukemia Sustained By the Persistence of Activated CD4+ CAR T-Cells.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper152664.htmlAdoptive transfer of chimeric antigen receptor (CAR)-reprogrammed T cells has shown promise in treating a variety of cancers. In chronic lymphocytic leukemia (CLL), functional persistence of CAR T-cells is a crucial predictor of long-term remissions, although the properties of long-term persistent CAR-engineered T cells have not been fully investigated. The fate of CD19-specific (CAR19) T-cells in two leukemia…

J. Joseph Melenhorst, Ph.D., Research Professor of Pathology and Laboratory Medicine Department: Pathology and Laboratory Medicine from the University of Pennsylvania speaks about the ASH 2021 Abstract 166 Decade-Long Remissions of Leukemia Sustained By the Persistence of Activated CD4+ CAR T-Cells.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper152664.htmlAdoptive transfer of chimeric antigen receptor (CAR)-reprogrammed T cells has shown promise in treating a variety of cancers. In chronic lymphocytic leukemia (CLL), functional persistence of CAR T-cells is a crucial predictor of long-term remissions, although the properties of long-term persistent CAR-engineered T cells have not been fully investigated. The fate of CD19-specific (CAR19) T-cells in two leukemia…

Adam M. Brufsky, MD, Ph.D., Professor of Medicine, Associate Chief, Division of Hematology/Oncology, Co-Director, Comprehensive Breast Cancer Center, Associate Director, Clinical Investigation at Magee-Womens Cancer Program, part of the UPMC Hillman Cancer Center of Medicine speaks about the Phase III DetermaIOâ„¢ Study.Link to Study:https://clinicaltrials.gov/ct2/show/NCT02620280Description in detail:Mononuclear cells and lymphocytes have been found in numerous triple negative and basal-like breast tumors, according to new research. Regardless of the kind of tumor invasion by mononuclear cells, immune regulatory checkpoints like PD-1 and its ligand B7-H1 (or PD-L1) have a deleterious impact on treatment outcomes. These findings imply that PD-L1 expression is an…

Lindsey E. Roeker, MD Hematologist Oncologist from Memorial Sloan Kettering Cancer Center speaks about the ASH 2021 Abstract – A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach.Link to Abstract:https://www.sciencedirect.com/science/article/abs/pii/S0006497121023892#!A summary -Context:While time-limited new agent combinations have shown good overall response rates and long-term responses in patients with chronic lymphocytic leukemia (CLL), they also have a high rate of adverse events and may overtreat many patients who are at low risk. Patients on indefinite ibrutinib monotherapy, on the other hand, are at…

Lindsey E. Roeker, MD Hematologist Oncologist from Memorial Sloan Kettering Cancer Center speaks about the ASH 2021 Abstract – A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach.Link to Abstract:https://www.sciencedirect.com/science/article/abs/pii/S0006497121023892#!A summary -Context:While time-limited new agent combinations have shown good overall response rates and long-term responses in patients with chronic lymphocytic leukemia (CLL), they also have a high rate of adverse events and may overtreat many patients who are at low risk. Patients on indefinite ibrutinib monotherapy, on the other hand, are at…

Neha Vapiwala, MD Professor of Radiation Oncology at the Hospital of the University of PennsylvaniaDepartment: Radiation Oncology, Penn Medicine speaks about the From JAMA Oncology – Diversity Trends by Sex and Underrepresented in Medicine Status Among US Radiation and Medical Oncology Faculty Over 5 Decades.Link to Abstract:https://pubmed.ncbi.nlm.nih.gov/34882189/A summary -Significance:It’s unclear how the historical exclusion of women and racial and ethnic minorities from medical school and, as a result, oncologic subspecialties, has influenced faculty diversity in oncology departments over time. Oncologic faculty diversity is a critical strategy for improving cancer care and addressing health inequities in an increasingly diverse US cancer community.Goals:To…

Neha Vapiwala, MD Professor of Radiation Oncology at the Hospital of the University of PennsylvaniaDepartment: Radiation Oncology, Penn Medicine speaks about the JAMA Oncology -  Diversity Trends by Sex and Underrepresented in Medicine Status Among US Radiation and Medical Oncology Faculty Over 5 Decades. Link to Abstract:https://pubmed.ncbi.nlm.nih.gov/34882189/A summary -Significance:It’s unclear how the historical exclusion of women and racial and ethnic minorities from medical school and, as a result, oncologic subspecialties, has influenced faculty diversity in oncology departments over time. Oncologic faculty diversity is a critical strategy for improving cancer care and addressing health inequities in an increasingly diverse US cancer community.Goals:To describe…

Dr. Stephen Malamud is the regional director of medical oncology at Nuvance Health. He is a board-certified and fellowship-trained physician who specializes in medical oncology for breast cancer. As an active clinical researcher, Dr. Malamud has been involved in trials that resulted in the approval of new cancer treatments. He is a nationally and internationally sought-after speaker. Dr. Malamud came from Mount Sinai Beth Israel Medical Center in New York before joining Nuvance Health. In this video he speaks about – An update of the targeted therapies for Her-2 and TNBC cancers with emphasis on the Destiny Trial (Enhertu) in…

Dr. Stephen Malamud is the regional director of medical oncology at Nuvance Health. He is a board-certified and fellowship-trained physician who specializes in medical oncology for breast cancer. As an active clinical researcher, Dr. Malamud has been involved in trials that resulted in the approval of new cancer treatments. He is a nationally and internationally sought-after speaker. Dr. Malamud came from Mount Sinai Beth Israel Medical Center in New York before joining Nuvance Health. In this video he speaks about – An update of the targeted therapies for Her-2 and TNBC cancers with emphasis on the Destiny Trial (Enhertu) in…

Saad Z. Usmani, MD MBA FACP, Chief, Myeloma Service at Memorial Sloan Kettering Cancer Center speaks about New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma.Link to Article:https://www.prnewswire.com/news-releases/new-data-from-majestec-1-study-show-continued-deep-and-durable-responses-of-teclistamab-bcmaxcd3-bispecific-antibody-in-treatment-of-heavily-pretreated-patients-with-multiple-myeloma-301443200.htmlThe MajesTEC-1 study of teclistamab, an off-the-shelf T-cell experimental redirecting bispecific antibody, is being evaluated for the treatment of patients with relapsed or refractory multiple myeloma. An overall response rate (ORR) of 62 percent was observed in heavily pretreated patients (n=150) across the Phase 1 and 2 studies who had received at least three prior lines of…

Saad Z. Usmani, MD MBA FACP, Chief, Myeloma Service at Memorial Sloan Kettering Cancer Center speaks about New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma.Link to Article:https://www.prnewswire.com/news-releases/new-data-from-majestec-1-study-show-continued-deep-and-durable-responses-of-teclistamab-bcmaxcd3-bispecific-antibody-in-treatment-of-heavily-pretreated-patients-with-multiple-myeloma-301443200.htmlThe MajesTEC-1 study of teclistamab, an off-the-shelf T-cell experimental redirecting bispecific antibody, is being evaluated for the treatment of patients with relapsed or refractory multiple myeloma. An overall response rate (ORR) of 62 percent was observed in heavily pretreated patients (n=150) across the Phase 1 and 2 studies who had received at least three prior lines of…

Colin C. Pritchard, MD, Professor, Co-Director, Genetics, and Solid Tumors Laboratory, Precision Diagnostics Platform Head, Brotman Baty Institute For Precision Medicine, UW Medicine Laboratory Medicine &amp; Pathology. In this video speaks about Inherited TP53 Variants and Risk of Prostate Cancer.Link to Article:https://newsroom.uw.edu/news/inherited-mutation-linked-aggressive-prostate-cancerLink to Study:https://www.sciencedirect.com/science/article/pii/S0302283821021394?via%3DihubAbstract:Backstory:Autosomal dominant multicancer predisposition, including Li-Fraumeni syndrome, is caused by inherited germline TP53 pathogenic and possibly pathogenic mutations (gTP53) (LFS). However, there is no documented link between gTP53 and prostate cancer.Goal:To see if gTP53 plays a role in prostate cancer predisposition.Participants, setting, and design:The incidence of prostate cancer in a cohort of LFS males and the prevalence…

Colin C. Pritchard, MD, Professor, Co-Director, Genetics, and Solid Tumors Laboratory, Precision Diagnostics Platform Head, Brotman Baty Institute For Precision Medicine, UW Medicine Laboratory Medicine &amp; Pathology. In this video speaks about Inherited TP53 Variants and Risk of Prostate Cancer.Link to Article:https://newsroom.uw.edu/news/inherited-mutation-linked-aggressive-prostate-cancerLink to Study:https://www.sciencedirect.com/science/article/pii/S0302283821021394?via%3DihubAbstract:Backstory:Autosomal dominant multicancer predisposition, including Li-Fraumeni syndrome, is caused by inherited germline TP53 pathogenic and possibly pathogenic mutations (gTP53) (LFS). However, there is no documented link between gTP53 and prostate cancer.Goal:To see if gTP53 plays a role in prostate cancer predisposition.Participants, setting, and design:The incidence of prostate cancer in a cohort of LFS males and the prevalence…

Jason Luke, MD, FACP, Director, Cancer Immunotherapeutics Center at UPMC Hillman Cancer Center speaks about FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection.Link to Article:https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-as-adjuvant-treatment-for-adult-and-pediatric-%e2%89%a512-years-of-age-patients-with-stage-iib-or-iic-melanoma-following-complete-resectio/The US Food and Drug Administration (FDA) has approved Merck’s anti-PD-1 medication, KEYTRUDA, for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following full resection. The FDA also increased the indication for KEYTRUDA as an adjuvant treatment for stage III melanoma after full resection to include pediatric patients…

Jason Luke, MD, FACP, Director, Cancer Immunotherapeutics Center at UPMC Hillman Cancer Center speaks about FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection.Link to Article:https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-as-adjuvant-treatment-for-adult-and-pediatric-%e2%89%a512-years-of-age-patients-with-stage-iib-or-iic-melanoma-following-complete-resectio/The US Food and Drug Administration (FDA) has approved Merck’s anti-PD-1 medication, KEYTRUDA, for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following full resection. The FDA also increased the indication for KEYTRUDA as an adjuvant treatment for stage III melanoma after full resection to include pediatric patients…

Jacob Laubach, MD, MPP from the Dana-Farber Cancer Institute speaks about the ASH 2021 Abstract – 79 Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper149024.htmlIntroduction:DARA is approved for NDMM and MM that have been previously treated. DARA plus RVd (D-RVd) improved the rate of stringent complete response (sCR) by the end of post-ASCT consolidation versus RVd (42.4 percent vs 32.0 percent, 1-sided P=0.068) in the primary analysis of the phase 2 GRIFFIN trial (NCT02874742) in autologous stem cell transplant…

Jacob Laubach, MD, MPP from the Dana-Farber Cancer Institute speaks about the ASH 2021 Abstract – 79 Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper149024.htmlIntroduction:DARA is approved for NDMM and MM that have been previously treated. DARA plus RVd (D-RVd) improved the rate of stringent complete response (sCR) by the end of post-ASCT consolidation versus RVd (42.4 percent vs 32.0 percent, 1-sided P=0.068) in the primary analysis of the phase 2 GRIFFIN trial (NCT02874742) in autologous stem cell transplant…

Javier Cortés, MD, Ph.D., Founder, and director of the International Breast Cancer Center (IBCC), in Madrid, Spain. Dr. Javier Cortés Castán is a leading oncologist of international renown in the research and treatment of breast cancer. Speaks about the SABCS 2021 Abstract – GS1-02 Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&amp;utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&amp;utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&amp;utm_medium=email&amp;utm_term=0_4612a17168-8777ae34f6-610272854&amp;mc_cid=8777ae34f6&amp;mc_eid=3a5efd49f4

Javier Cortés, MD, Ph.D., Founder, and director of the International Breast Cancer Center (IBCC), in Madrid, Spain. Dr. Javier Cortés Castán is a leading oncologist of international renown in the research and treatment of breast cancer. Speaks about the SABCS 2021 Abstract – GS1-02 Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&amp;utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&amp;utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&amp;utm_medium=email&amp;utm_term=0_4612a17168-8777ae34f6-610272854&amp;mc_cid=8777ae34f6&amp;mc_eid=3a5efd49f4

Ruben A. Mesa, MD, FACP from Mays Cancer Center, UT Health San Antonio Cancer Center speaks about the ASH 2021 Abstract – 1490 INDEPENDENCE: A Phase 3 Study of Efficacy and Safety of Luspatercept Versus Placebo in Patients with Myeloproliferative Neoplasm-Associated Myelofibrosis on JAK2 Inhibitor Therapy and Requiring Red Blood Cell Transfusions.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper145717.htmlBackground:Ineffective erythropoiesis, faulty bone marrow (BM) function, and fibrosis, and a higher likelihood of progression to acute myeloid leukemia are all symptoms of myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) (AML). Anemia is present in up to 60% of patients (pts) at the time of diagnosis, and all pts…

Ruben A. Mesa, MD, FACP from Mays Cancer Center, UT Health San Antonio Cancer Center speaks about the ASH 2021 Abstract – 1490 INDEPENDENCE: A Phase 3 Study of Efficacy and Safety of Luspatercept Versus Placebo in Patients with Myeloproliferative Neoplasm-Associated Myelofibrosis on JAK2 Inhibitor Therapy and Requiring Red Blood Cell Transfusions.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper145717.htmlBackground:Ineffective erythropoiesis, faulty bone marrow (BM) function, and fibrosis, and a higher likelihood of progression to acute myeloid leukemia are all symptoms of myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) (AML). Anemia is present in up to 60% of patients (pts) at the time of diagnosis, and all pts…

Sara Tolaney, MD from Dana Farber Cancer Institute speaks about the SABCS 2021 Presentation – Heterogeneity in treatment outcomes for HER2+ breast cancer – clinical management strategies.

Sara Tolaney, MD from Dana Farber Cancer Institute speaks about the SABCS 2021 Presentation – Heterogeneity in treatment outcomes for HER2+ breast cancer – clinical management strategies.

Courtney D. DiNardo, MD, MSCE, is a clinical researcher who focuses on prognostication and customized treatments for myeloid malignancies patients at The University of Texas Anderson Cancer Center. Speaks about the ASH 2021 Abstract – 1243 Outcomes for Patients with Late-Stage Mutant-IDH2 (mIDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper147593.htmlBackground:For older patients (pts) with R/R AML, the prognosis is poor, especially if numerous lines of AML treatment (Tx) have failed. After each Tx failure, achieving a response becomes increasingly difficult, and many patients are unable…

Courtney D. DiNardo, MD, MSCE, is a clinical researcher who focuses on prognostication and customized treatments for myeloid malignancies patients at The University of Texas Anderson Cancer Center. Speaks about the ASH 2021 Abstract – 1243 Outcomes for Patients with Late-Stage Mutant-IDH2 (mIDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper147593.htmlBackground:For older patients (pts) with R/R AML, the prognosis is poor, especially if numerous lines of AML treatment (Tx) have failed. After each Tx failure, achieving a response becomes increasingly difficult, and many patients are unable…

Geoffrey B. Pelz, MD, Thoracic Surgical Oncology, Hackensack Meridian Health speaks about the New GPS-Like Technology to Detect &amp; Help Treat Lung Cancer at Hackensack University Medical Center.Link to Article:http://www.amboyguardian.com/2021/10/08/new-gps-like-technology-to-detect-help-treat-lung-cancer-at-hackensack-university-medical-centerAs we approach World Lung Day on September 25, 2021, a day dedicated to raising awareness about the importance of lung health, lung cancer remains the leading cause of cancer death for both men and women in the United States, owing to its difficulty in early detection.Certain lung lesions may be dangerous or impossible to identify with typical biopsy techniques. As a result, lung cancer can progress before it is discovered.While…

Geoffrey B. Pelz, MD, Thoracic Surgical Oncology, Hackensack Meridian Health speaks about the New GPS-Like Technology to Detect &amp; Help Treat Lung Cancer at Hackensack University Medical Center.Link to Article:http://www.amboyguardian.com/2021/10/08/new-gps-like-technology-to-detect-help-treat-lung-cancer-at-hackensack-university-medical-centerAs we approach World Lung Day on September 25, 2021, a day dedicated to raising awareness about the importance of lung health, lung cancer remains the leading cause of cancer death for both men and women in the United States, owing to its difficulty in early detection.Certain lung lesions may be dangerous or impossible to identify with typical biopsy techniques. As a result, lung cancer can progress before it is discovered.While…

Maureen M. Achebe, MD, MPH, Associate Physician, Brigham and Women’s Hospital, Assistant Professor of Medicine, Harvard Medical School, Associate Director, Brigham and Women’s Hospital Infusion Center speaks about the ASH 2021 Abstract – 3114 Long-Term Safety and Efficacy of Voxelotor for Patients with Sickle Cell Disease: Results from an Open-Label Extension of the Phase 3 HOPE Trial.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper153582.htmlBackground:Sickle cell disease (SCD) is a lifelong inherited blood illness caused by a mutation in the hemoglobin (Hb) subunit gene, which results in the development of sickle hemoglobin (HbS). Hemolysis, chronic anemia, and vaso-occlusive crises are all caused by HbS polymerization, which…

Maureen M. Achebe, MD, MPH, Associate Physician, Brigham and Women’s Hospital, Assistant Professor of Medicine, Harvard Medical School, Associate Director, Brigham and Women’s Hospital Infusion Center speaks about the ASH 2021 Abstract – 3114 Long-Term Safety and Efficacy of Voxelotor for Patients with Sickle Cell Disease: Results from an Open-Label Extension of the Phase 3 HOPE Trial.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper153582.htmlBackground:Sickle cell disease (SCD) is a lifelong inherited blood illness caused by a mutation in the hemoglobin (Hb) subunit gene, which results in the development of sickle hemoglobin (HbS). Hemolysis, chronic anemia, and vaso-occlusive crises are all caused by HbS polymerization, which…

Sara A. Hurvitz, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA speaks about the SABCS 2021 Abstract – GS3-01 Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03.Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&amp;utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&amp;utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&amp;utm_medium=email&amp;utm_term=0_4612a17168-8777ae34f6-610272854&amp;mc_cid=8777ae34f6&amp;mc_eid=3a5efd49f4

Sara A. Hurvitz, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA speaks about the SABCS 2021 Abstract – GS3-01 Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03.Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&amp;utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&amp;utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&amp;utm_medium=email&amp;utm_term=0_4612a17168-8777ae34f6-610272854&amp;mc_cid=8777ae34f6&amp;mc_eid=3a5efd49f4

Marwan Fakih, MD, The Judy &amp; Bernard Briskin Distinguished Director of Clinical Research; Professor, Department of Medical Oncology &amp; Therapeutics Research; Associate Director for Clinical Research, Comprehensive Cancer Center; Medical Director, Judy &amp; Bernard Briskin Center for Clinical Research; Co-director, Gastrointestinal Cancer Program at City of Hope. Speaks about Sotorasib for previously treated colorectal cancers with KRAS p.G12C mutation (CodeBreaK100): an interim analysis of a single-arm, Phase 2 trial.Link to Article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00605-7/fulltextBackstory:In the CodeBreaK100 phase 1 trial, sotorasib, a selective, irreversible KRASG12C protein inhibitor, showed monotherapy clinical activity in KRASG12C-mutated solid tumors, including colorectal cancer. In phase 2 of the trial,…

Marwan Fakih, MD, The Judy &amp; Bernard Briskin Distinguished Director of Clinical Research; Professor, Department of Medical Oncology &amp; Therapeutics Research; Associate Director for Clinical Research, Comprehensive Cancer Center; Medical Director, Judy &amp; Bernard Briskin Center for Clinical Research; Co-director, Gastrointestinal Cancer Program at City of Hope. Speaks about Sotorasib for previously treated colorectal cancers with KRAS p.G12C mutation (CodeBreaK100): an interim analysis of a single-arm, Phase 2 trial.Link to Article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00605-7/fulltextBackstory:In the CodeBreaK100 phase 1 trial, sotorasib, a selective, irreversible KRASG12C protein inhibitor, showed monotherapy clinical activity in KRASG12C-mutated solid tumors, including colorectal cancer. In phase 2 of the trial,…

Mahmoud Elsawy, MD, MSc Assistant Professor, Division of Hematology, Dalhousie University. Medical Director of IEC Therapy Program, QEII Health Sciences Center, NS, Canada speaks about the ASH 2021 Abstract – 430 Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7). Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper147598.htmlBackground:Patients with large B-cell lymphoma (LBCL) who relapse early or are unresponsive to first-line therapy have dismal outcomes. Furthermore, patients receiving second-line standard-of-care (SOC) therapy frequently report a low quality of life connected to their health (QoL; Lin…

Mahmoud Elsawy, MD, MSc Assistant Professor, Division of Hematology, Dalhousie University. Medical Director of IEC Therapy Program, QEII Health Sciences Center, NS, Canada speaks about the ASH 2021 Abstract – 430 Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7).Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper147598.htmlBackground:Patients with large B-cell lymphoma (LBCL) who relapse early or are unresponsive to first-line therapy have dismal outcomes. Furthermore, patients receiving second-line standard-of-care (SOC) therapy frequently report a low quality of life connected to their health (QoL; Lin V,…

Avanish Vellanki, MBA and Robert Doebele, MD, Ph.D., Chief Executive Officer, and Co-founder, and President, Chief Scientific Officer &amp; Co-founder of Rain Therapeutics discusses Rain Therapeutics Initiates Phase 3 MANTRA Clinical Trial of Milademetan for De-differentiated Liposarcoma and Provides Patient Update from Prior Clinical Program.Link to Article:https://www.globenewswire.com/news-release/2021/07/20/2265589/0/en/Rain-Therapeutics-Initiates-Phase-3-MANTRA-Clinical-Trial-of-Milademetan-for-De-differentiated-Liposarcoma-and-Provides-Patient-Update-from-Prior-Clinical-Program.htmlLink to Study:https://clinicaltrials.gov/ct2/show/NCT04979442Rain Therapeutics Inc., a clinical-stage company focused on precision oncology therapeutics, announced today that the first patient in the multicenter, open-label, Phase 3 registrational study (MANTRA) evaluating milademetan (RAIN-32), an oral mouse double minute 2 (MDM2) inhibitor, for the treatment of DD LPS has been randomized.The MANTRA trial is a randomized, multicenter,…

Avanish Vellanki, MBA and Robert Doebele, MD, Ph.D., Chief Executive Officer, and Co-founder, and President, Chief Scientific Officer &amp; Co-founder of Rain Therapeutics discusses Rain Therapeutics Initiates Phase 3 MANTRA Clinical Trial of Milademetan for De-differentiated Liposarcoma and Provides Patient Update from Prior Clinical Program.Link to Article:https://www.globenewswire.com/news-release/2021/07/20/2265589/0/en/Rain-Therapeutics-Initiates-Phase-3-MANTRA-Clinical-Trial-of-Milademetan-for-De-differentiated-Liposarcoma-and-Provides-Patient-Update-from-Prior-Clinical-Program.htmlLink to Study:https://clinicaltrials.gov/ct2/show/NCT04979442Rain Therapeutics Inc., a clinical-stage company focused on precision oncology therapeutics, announced today that the first patient in the multicenter, open-label, Phase 3 registrational study (MANTRA) evaluating milademetan (RAIN-32), an oral mouse double minute 2 (MDM2) inhibitor, for the treatment of DD LPS has been randomized.The MANTRA trial is a randomized, multicenter,…

Matthew A. Ingham, MD, Assistant Professor of Medicine in the Division of Hematology and Oncology at Columbia University Vagelos College of Physicians and Surgeons speaks about Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTOS) 2021 Virtual Annual Meeting.Intensity Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of proprietary immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announced today that data from…

Matthew A. Ingham, MD, Assistant Professor of Medicine in the Division of Hematology and Oncology at Columbia University Vagelos College of Physicians and Surgeons speaks about Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTOS) 2021 Virtual Annual Meeting.Intensity Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of proprietary immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announced today that data from…

Terry Mamounas, MD, MPH, FACS from Orlando Health Cancer Institute speaks about the SABCS 2021 Presentation – Refining Axillary Management After Neoadjuvant Chemotherapy – What Does The Evidence Support.

Terry Mamounas, MD, MPH, FACS from Orlando Health Cancer Institute speaks about the SABCS 2021 Presentation – Refining Axillary Management After Neoadjuvant Chemotherapy – What Does The Evidence Support.

Karuppiah Kannan, Ph.D. Senior Director – Global Program Leader at Takeda Oncology speaks about the ASH 2021 Abstracts – 2488 TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data, and 2742 Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma.Link to Abstract 2488:https://ash.confex.com/ash/2021/webprogram/Paper152225.htmlBackground:TAK-981 is the first SUMOylation small-molecule inhibitor to reach clinical studies. Small ubiquitin-like modifier (SUMO) proteins are activated and covalently bound to substrate proteins during SUMOylation, a post-translational modification. Type I…

Karuppiah Kannan, Ph.D. Senior Director – Global Program Leader at Takeda Oncology speaks about the ASH 2021 Abstracts – 2488 TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data, and 2742 Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma.Link to Abstract 2488:https://ash.confex.com/ash/2021/webprogram/Paper152225.htmlBackground:TAK-981 is the first SUMOylation small-molecule inhibitor to reach clinical studies. Small ubiquitin-like modifier (SUMO) proteins are activated and covalently bound to substrate proteins during SUMOylation, a post-translational modification. Type I…

Naval Daver, MD from The University of Texas MD Anderson Cancer Center speaks about the ASH 2021 Abstract – 3426 A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine in Previously Untreated Patients with TP53-Mutant Acute Myeloid Leukemia.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper145208.htmlBackground:Magrolimab (Hu5F9-G4) is an antibody that kills leukemia stem cells by encouraging tumor phagocytosis by inhibiting CD47, a macrophage immune checkpoint and “don’t eat me” signal on cancer cells. Hypomethylating drugs work along with magrolimab to increase phagocytosis by eliciting “eat me” signals on leukemic blasts. In frontline acute myeloid leukemia (AML) patients…

Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician’s Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia (ENHANCE-2 Clinical Trial) The study we are conducting here is a randomized phase 3 international study of Azacitidine Magrolimab (Hu5F9-G4), versus investigator choice therapy of either Azacitidine Venetoclax or intensive three plus seven, specifically in a molecular subset of TP53-mutated (TP53m), acute myeloid leukemia. The goal of this study is to see whether the combination treatment of Azacitidine with CD47 immune therapy Magrolimab (Hu5F9-G4) could…

Professor Jonathan Wall, Ph.D., Distinguished Professor and Director of the University of Tennessee Graduate School of Medicine’s Amyloidosis and Cancer Theranostics Program speaks about the ASH 2021 Abstract – 2952 Detection of Systemic AL Amyloidosis By 124I-p5+14 PET/CT Imaging – Providing the Complete Picture for Diagnosis.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper154327.htmlBackground:The deposition of fibrils in abdominothoracic organs, particularly the heart, liver, spleen, and kidneys, is associated with Immunoglobulin light chain-associated (AL) amyloidosis, resulting in organ failure and substantial morbidity. The fluctuating quantities of amyloid load and the varied organ presentation of amyloid make accurate and speedy diagnosis difficult. Organ biopsy and inferences based…

Craig Eagle, MD, FRACP, FRCPA from Guardant Health. In this video, he explains that the Study Shows Guardant360® Liquid Biopsy Test Helps Guide Treatment for Patients with HER2-Driven Metastatic Colorectal Cancer. https://www.businesswire.com/news/home/20211111006023/en/Study-Shows-Guardant360%C2%AE-Liquid-Biopsy-Test-Helps-Guide-Treatment-for-Patients-with-HER2-Driven-Metastatic-Colorectal-CancerThe TRIUMPH study looked at the efficacy of pertuzumab with trastuzumab in patients with mCRC who had HER2 amplification as established by circulating tumor DNA (ctDNA) analysis or tissue genotyping. EGFR-targeting monoclonal antibodies had previously been used to treat all of the patients. Additional exploratory studies were conducted to explore if ctDNA genotyping might be used to predict treatment success, follow response, and uncover resistance mechanisms.While the efficacy of…

Professor Jonathan Wall, Ph.D., Distinguished Professor and Director of the University of Tennessee Graduate School of Medicine’s Amyloidosis and Cancer Theranostics Program speaks about the ASH 2021 Abstract – 2952 Detection of Systemic AL Amyloidosis By 124I-p5+14 PET/CT Imaging – Providing the Complete Picture for Diagnosis.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper154327.htmlBackground:The deposition of fibrils in abdominothoracic organs, particularly the heart, liver, spleen, and kidneys, is associated with Immunoglobulin light chain-associated (AL) amyloidosis, resulting in organ failure and substantial morbidity. The fluctuating quantities of amyloid load and the varied organ presentation of amyloid make accurate and speedy diagnosis difficult. Organ biopsy and inferences based…

David Spiegel, MD from Stanford University speaks about the SABCS Presentation – Hypnosis and Mindfulness.Go to the links below to download the app. https://apps.apple.com/us/app/reveri/id1547020650https://play.google.com/store/apps/details?id=com.reveri.reverihealth&amp;hl=en_US&amp;gl=US

David Spiegel, MD from Stanford University speaks about the SABCS Presentation – Hypnosis and Mindfulness.Go to the links below to download the app. https://apps.apple.com/us/app/reveri/id1547020650https://play.google.com/store/apps/details?id=com.reveri.reverihealth&amp;hl=en_US&amp;gl=US

Erika P. Hamilton, MD, Director, Breast Cancer and Gynecologic Cancer Research, Sarah Cannon Research Institute at Tennessee Oncology speak about the SABCS 2021 Abstract – OT1-13-01 HER2CLIMB-04: phase 2 trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases.